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PCa (Gleason grade 4), and metastatic PCa (liver), respectively. (E-H)
Corresponding hematoxylin and eosin (H&E) staining of adjacent slices.
Scalar bar, 100 µm. (I-L) High magnification SRL and two-photon
fluorescence images of the lesions shown in (A-D) (grey: SRL, green: twophoton fluorescence). Autofluorescent granules and LDs indicated by red
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arrows. Scalar bar, 20 µm. (M) LD area fraction in 58 specimens: normal
prostate (n = 19), low-grade PCa (n = 9), high-grade PCa (n = 11), and
metastatic PCa (n = 9). Mean of LD area fraction indicated by red line. n.s.
means not significant. (N) Raman spectra of autofluorescent granules in
normal prostate, LDs in PCa, and pure cholesteryl oleate. Spectral intensity
was normalized by CH2 bending band at 1442 cm-1. Black arrows indicate the
bands of cholesterol rings at 702 cm-1. (O) CE molar percentage in LDs of
low-grade PCa (n = 9), high-grade PCa (n = 11), and metastatic PCa (n = 9).
Error bars represent SD. .................................................................................. 37
Figure 2.2 CE accumulation in normal prostate, BPH, PIN, or prostatitis. (A-I) Label-free
SRL and two-photon fluorescence imaging of normal prostate, BPH, and PIN.
(J-L) Label-free SRL and two-photon fluorescence imaging of prostatitis
tissue. Grey: SRL; Green: two-photon fluorescence. Scalar bar: 100 µm for
large-area images, 20 µm for high-magnification images. (M) Normalized
two-photon fluorescence spectrum of autofluorescent granule in normal
prostate. (N-O) SRL and two-photon fluorescence images of normal and
cancerous mouse prostate tissues in a spontaneous PCa TRAMP model. Scalar
bar, 20 µm. (P) Raman spectra of different autofluorescent granules in one
normal prostate tissue. (Q) Raman spectra of autofluorescent granules in BPH
and PIN lesion. (R) Raman spectra of LDs in different cells in one PCa
specimen. (S) Raman spectra of CE-TG emulsions with eight different CE:TG
molar ratios, ranging from 0:10 to 10:0. (T) Calibration curve for
quantification of CE percentage out of total neutral lipid. (U) Mass spectra of
lipids extracted from normal prostate and high-grade PCa tissues. ................ 39
Figure 2.3 CE accumulation is not correlated with androgen signaling. (A) SRL images
of various types of cells, including RWPE1, LNCaP-LP, LNCaP-HP, PC-3,
DU145, and C4-2. LDs indicated by green arrows. (B) Raman spectra of LDs
in different cell lines shown in (A). Spectral intensity was normalized by the
peak at 1442 cm-1. Black arrows indicate the bands of cholesterol rings at 702
cm-1. (C) Quantitation of LD amount and CE percentage. LD amount was
normalized by the RWPE1 group. Error bars represent SEM. n > 5. **: p <
0.005, ***: p < 0.0005. (D) Nuclear translocation of AR in LNCaP-LP and
LNCaP-HP cells. Blue: DAPI, Red: AR immunofluorescence. Scalar bar, 10
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Figure 2.4 CE measurements of RWPE1 and 22Rv-1 cells in various culture conditions.
(A) CE measurement of RWPE1 cells cultured in regular serum-free medium
and the medium supplemented with 10% FBS. (B) SRL images of 22Rv-1
cells treated with different concentrations of dihydrotestosterone (DHT). DHT
was diluted in phenol-red free RPMI + 10% charcoal-stripped serum, 4 days
incubation. Scalar bar, 10 µm. ........................................................................ 44
Figure 2.5 CE accumulation is induced by loss of PTEN and activation of PI3K/AKT
pathway. (A) CE levels in PC-3 cells transfected with PTENWT plasmid for 3
days. Raman spectra of LDs in control and PTEN-overexpressed cells are
shown on the left. The band of cholesterol rings at 702 cm-1 nearly
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disappeared after the treatment, as indicated by the arrows. Quantitation of CE
percentage and LD amount is shown on the right. n > 5. (B) CE measurement
of DU145 cells transfected with PTEN shRNA lentiviral particle for 3 days.
Raman spectra of LDs in control and transfected cells are shown on the left.
The band of cholesterol rings at 702 cm-1 significantly increased after the
treatment, as indicated by the arrows. Quantitation of CE percentage and LD
amount is shown on the right. n > 5. (C) SRL images of cells treated with
DMSO as control, LY294002 (50 µM, 3d), MK2206 (10 µM, 2d), rapamycin
(100 nM, 2d), and SREBP-1 and -2 siRNA (2d transfection). LDs indicated by
green arrows. Scalar bar, 10 µm. (D) Quantitation of CE percentage and LD
amount in cells shown in (C). n > 5. (E) Immunoblot of the antibodies against
p-AKT, p-S6, SREBP-1 and -2, and β-Actin in cells treated with DMSO as
control (Ctl), LY294002 (LY), MY2206 (MK), and rapamycin (Rapa). P:
precursor form, C: cleaved form. The expression levels of p-AKT and p-S6
were reduced after inhibitor treatments as expected. Error bars represent SEM.
***: p < 0.0005. .............................................................................................. 46
Figure 2.6 CE accumulation is not correlated with androgen signaling, but rather induced
by loss of PTEN and activation of PI3K/AKT pathway. (A) CE measurement
of DU145 cell treated with a potent inhibitor of PTEN, BPV(pic) (10 µM) for
3 days. Raman spectra of LDs in control and transfected cells are shown on
the upper row. The band of cholesterol rings at 702 cm-1 significantly
increased after the treatment, as indicated by the arrows. Quantitation of CE
percentage and LD amount is shown on the bottom row. n > 5. (B) Raman
spectra of LDs in PC-3 cells undergone various treatments including
LY294002 (50 µM, 3d), MK2206 (10 µM, 2d), rapamycin (100 nM, 2d),
SREBP-1 and -2 siRNA (2d transfection). The bands of cholesterol rings at
702 cm-1 were significantly reduced after the treatments, as indicated by the
arrows. (C) LD amount and CE percentage of LNCaP-HP cells treated with
DMSO as control, LY294002 (50 µM, 3d), MK2206 (10 µM, 2d), and
rapamycin (100 nM, 2d). (D) Immunofluorescence images of DAPI (blue) and
AR (red) in LNCaP-LP cells and LNCaP-HP cells treated with DMSO as
control, LY294002, MK2206, and rapamycin. (E) Immunoblot of the
antibodies against PTEN, SREBP-1 or -2 (precursor forms), and β-Actin in
control, PTEN overexpressed, SREBP-1 or -2 siRNA-transfected PC-3 cells.
......................................................................................................................... 47
Figure 2.7 CE accumulation arises from enhanced uptake of exogenous LDL and
involves cholesterol esterification by ACAT-1. (A) LD amount and CE
percentage in PC-3 cells treated with or without simvastatin (10 µM, 1d), n >
5. (B) SRL images and quantitation of LD amount in PC-3 cells treated with
LPDS (10%, 1d) and subsequent LDL re-addition (45 µg/ml, 1d), n = 6. LDs
indicated by green arrows. (C) Quantitation and representative images of DiILDL uptake by PC-3 cells treated with DMSO as control, LY294002, and
rapamycin (grey: SRL, green: two-photon fluorescence), n = 5. DiI-LDL
intensity was normalized by the control group. (D) Raman spectra of LDs and

xiii
Figure

Page

quantitation of LD amount and CE percentage in PC-3 cells treated with
avasimibe (7.5 µM, 1d) and ACAT-1 shRNA (3d transfection). n > 5. Spectral
intensity was normalized by the peak at 1442 cm-1. The bands of cholesterol
rings at 702 cm-1 nearly disappeared after the treatments, as indicated by the
arrows. LD amount was normalized by the control group in (B, D). (E) Mass
spectra of lipids extracted from control and avasimibe-treated PC-3 cells (7.5
μM, 2d). The m/z 668 peak stands for cholesteryl oleate (CE 18:1). Error bars
represent SEM. **: p < 0.005, ***: p < 0.0005. Scalar bar, 10 µm. LPDS:
lipoprotein deficient serum; DiI-LDL: DiI-LDL. ........................................... 49
Figure 2.8 LDs in CE-poor cells do not arise from exogenous LDL, whereas CE
accumulation in CE-rich cells arises from enhanced uptake of exogenous LDL.
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CE-poor cancer cells, including LNCaP-LP, DU145, and C4-2, before and
after LPDS treatment (1d). LD amounts in cells before treatments were
normalized for each cell line. (C-D) Representative images and quantitation of
DiI-LDL uptake in various cell lines, including RWPE1, LNCaP-LP, LNCaPHP, PC-3, DU145, and C4-2. DiI-LDL treatment: 20 µg/ml for 3 hr. Grey:
SRL; Green: two-photon fluorescence. (E) Immunoblot of the antibodies
against LDLr, ACAT-1, and β-Actin in PC-3 cells treated with DMSO as
control, LY294002 (50 µM, 3d), MK2206 (10 µM, 2d), and rapamycin (100
nM, 2d). (F) Quantitation of DiI-LDL uptake in PC-3 cells transfected with
SREBP-1 siRNA. (G) SRL images and Raman spectra of LDs in PC-3 cells
with and without Sandoz 58-035 treatment (10 µM, 1d). The bands of
cholesterol rings at 702 cm-1 nearly disappeared after the treatments, as
indicated by the arrows. (H) Effect of avasimibe treatment (7.5 μM, 2d) on
fraction of CE out of total cholesterol in PC-3 cells, measured by biochemical
assay. (I) Relative levels of cholesteryl oleate (CE 18:1) in control and
avasimibe-treated PC-3 cells (7.5 μM, 2d), measured by mass spectrometry
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against ACAT-1 and β-Actin in control and ACAT-1 siRNA-transfected PC-3
cells. Scalar bar = 10 µm. Error bars represent SEM. *: p < 0.05. **: p < 0.005,
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Figure 2.9 CE depletion impairs human PCa aggressiveness. (A) IC50 curves of
avasimibe and Sandoz 58-035 treatments on PC-3 cells. n = 6 per group. (B)
Flow cytometry analysis of cell cycle in control and avasimibe-treated PC-3
cells (n = 3). (C, D) Quantitation of migrated and invaded PC-3 cells that were
pretreated with DMSO as control, avasimibe (5 µM), Sandoz 58-035 (SaH, 10
µM), and ACAT-1 shRNA for 2d (n = 3). And quantitation of migrated and
invaded PTEN knockdown (PTEN-KD) DU145 cells that were pretreated
with DMSO as control and avasimibe (5 µM) for 1d (n = 3). (E) Relative
tumor volume of PC-3 xenograft (n = 9). Relative tumor volume = tumor
volume / initial tumor volume (day 0) for each mouse. Representative tumors
harvested on day 30 are shown in the inset. Scalar bar, 1 cm. (F) Weight of
tumor tissues harvested from mice (n = 8). (G) Body weight of mice over 30-
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day treatments (n = 9). (H) CE percentage of tumor tissues harvested from mice (n = 5).
(I) Representative images of H&E staining, IHC of Ki67, and TUNEL
labeling (blue: DAPI, cyan: TUNEL-positive) of vehicle and avasimibe
groups. Scalar bar, 100 µm. (J) Percentage of Ki67 and TUNELpositive cells
in vehicle and avasimibe groups (n = 5). Error bars represent SEM. *: p < 0.05,
**: p < 0.005, ***: p < 0.0005. ....................................................................... 53
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and C4-2, treated with avasimibe. n = 6 per group. (C) IC50 curves of
avasimibe treatment on LNCaP-HP cells and DGAT-1 inhibitor A922500
treatment on PC-3 cells. n = 6 per group. (D) Viability of PC-3 cells
transfected with ACAT-1 shRNA for 3 days. And viability of PTEN
knockdown (PTEN-KD) DU145 cells treated with avasimibe (7.5 µM) for 2
days. (E) Images of migration and invasion of PC-3 cells pre-treated with
avasimibe (5 µM, 2d). Red: PI staining. Scalar bar, 50 µm. (F) Quantitation
of migrated and invaded PC-3 cells pre-treated with DGAT-1 inhibitor
A922500 (10 µM, 2d), n = 3. (G) Relative tumor volume of PC-3 xenograft
(n = 8). (H) Weight of tumor tissues (n = 8). (I) Body weight of mice (n = 8).
(J) H&E staining of tissue sections. Scalar bar, 100 µm. (K) Raman spectra
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ABSTRACT

Yue, Shuhua. Ph.D., Purdue University, December 2013. Altered Cholesterol Metabolism
in Human Cancers Unraveled by Label-free Spectroscopic Imaging. Major Professor: JiXin Cheng.

Despite tremendous scientific achievements, cancer remains the second leading
cause of death in the United States. Metabolic reprogramming has been increasingly
recognized as a core hallmark of cancer. My dissertation work identified novel diagnostic
markers and therapeutic targets for human cancers through the study of cholesterol in
cancer cells.
Enabled by label-free Raman spectromicroscopy, we performed the first
quantitative analysis of lipogenesis at single cell level in human patient cancerous tissues.
Our imaging data revealed an unexpected, aberrant accumulation of esterified cholesterol
in lipid droplets of high-grade prostate cancer and metastases, but not in normal prostate,
benign prostatic hyperplasia, or prostatitis. Biochemical and molecular biological studies
showed that such cholesteryl ester accumulation was a consequence of loss of tumor
suppressor PTEN and subsequent activation of PI3K/AKT pathway in prostate cancer
cells. Furthermore, we found that such accumulation arose from significantly enhanced
uptake of exogenous lipoproteins and required cholesterol esterification. Depletion of
cholesteryl ester storage using pharmacological inhibitors or RNA interference
significantly reduced cancer proliferation, impaired cancer invasion capability, and

xxv
suppressed tumor growth in mouse xenograft models with negligible toxicity. These
findings open new opportunities for diagnosing and treating late-stage prostate cancer by
targeting the altered cholesterol metabolism.
My thesis work also found that cholesterol-rich domains on plasma membranes
can be used as a marker for the loss of basoapical polarity, one of the earliest changes
observed in breast neoplasia. Raman microspectroscopy revealed that in polarized acini
lipids were more ordered at the apical membranes compared to basal membranes, and
that an inverse situation occurred in acini that lost apical polarity upon treatment with
Ca2+-chelator EGTA. This method allowed us to detect the disruption of apical polarity
by dietary breast cancer risk factor, ω6 fatty acid, even when the effect was too moderate
to permit a conclusive assessment by traditional immunostaining method. Collectively,
label-free Raman analysis of cholesterol-rich membrane domains in mammary acini
provides an effective screening platform to identify risk factors that initiate breast cancer.
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CHAPTER 1. INTRODUCTION

Despite tremendous scientific achievements, cancer remains a major global
burden of disease. According to the most recent data on cancer incidence and mortality
from the National Cancer Institute, and the Center for Disease Control and Prevention,
cancer is the second leading cause of death in the United States with a total of 1,660,290
new cases and 580,350 cancer deaths projected to occur in 2013 [1]. In other words, in
every one minute there is one person dying from cancer in the United States. With
significant improvements in prevention and control of cardiovascular diseases, cancer
may soon become the number one killer to human beings worldwide.
Since the first observation of chromosomal abnormalities in cancers [2] and
numerous following studies on genetic transformations responsible for carcinogenesis [35], cancer has been classically considered as a multistep genetic disease caused by a
series of abnormal activation of oncogenes and/or inactivation of tumor suppressor genes
[6]. Although Warburg discovered a characteristic metabolic pattern for cancer as early
as 1920s [7], metabolic reprogramming has long been underappreciated by the majority
of cancer researchers. Owing to recent advances in analytic tools and progress of cancer
genomics, many key oncogenic transformations in cancer cells have been found to drive
metabolic signaling pathways that differ from their normal counterparts by high rates of
glycolysis and biosynthesis of essential macromolecules to fuel rapid growth [8].
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Meanwhile, some of the metabolic alterations become necessary for malignant
transformations [8]. Such connections between oncogenic transformations and metabolic
alterations make cancer metabolism one of the most intense areas of research in cancer
biology. Many excellent review articles have been published recently [8-11]. The
renewed interest in cancer metabolism is opening translational opportunities for the
diagnosis [12] and treatment [13] of human cancers. Most if not all cancers have been
suggested to share the same essential alterations in cell physiology, namely the six
hallmarks of cancer summarized by Hanahan and Weinberg in 2000 [14]. Metabolic
reprogramming has been increasingly recognized as a new hallmark of cancer [15].
While normal cells reply on mitochondrial oxidative phosphorylation to generate
the energy needed for cellular processes, most cancer cells activate glycolysis even in the
presence of adequate oxygen, a process known as aerobic glycolysis or Warburg effect
[16]. Although enough evidence has support the crucial role of aerobic glycolysis in
cancer development, the underlying mechanism why cancer cells prefer to use glycolysis,
a very inefficient way to generate ATP, is still under investigation [17]. Other than
energy metabolism, cancer cells also adapt metabolic pathways to facilitate the
biosynthesis of macromolecules needed for a new cell. The advances in proteomics
greatly stimulated research, revealing the key roles of amino acids, especially glutamine
[18, 19] and glycine [20], in cancer development.
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1.1

Fat and Cancer

Whereas alterations to metabolism of glucose and amino acids have been
extensively studied [16, 18, 20], the metabolism of another essential macromolecule,
lipids, in cancer is an under-studied field [21]. Lipids are a group of water-insoluble
molecules that include fatty acids, sterols, phospholipids, sphingolipids, TGs, etc. [22]
Phospholipids, together with sterols and sphingolipids, form building blocks of biological
membranes. TGs serve as energy storage for cells. Fatty acids provide hydrocarbon
chains to produce more complex lipids, and in the meanwhile can be oxidized into acetylCoA for further biosynthesis or energy supply if no glucose is available. Emerging
evidence also supports that lipids can also function as signaling molecules that have
profound effect on a wide range of biological processes, including cell proliferation, cell
differentiation, apoptosis, migration, and inflammation [23]. Recently, lipids have
received considerable amount of attention in the field of cancer research, largely due to
increasing evidence on the link between obesity, dietary fat intake, blood lipid levels and
cancer risk.

1.1.1

Whole-body Fat Metabolism and Cancer

Obesity is a strong risk factor for many prevalent metabolic diseases, including
cardiovascular disease, type 2 diabetes, and cancer [24-28]. Obesity has been reported to
increase rates of both cancer incidence and mortality for a variety of cancers, including
those of the oesophagus [29], colorectum [30], postmenopausal breast [31], endometrium
[32], kidney [33], pancreas [34], liver [35], gallbladder [36], lung [37], cervix [38], ovary
[39], prostate [40], and haematopoietic cancers [41]. It has been estimated that 14% of all
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deaths from cancer in men and 20% of those in women may be due to obesity in the U.S.
The currently proposed factors linking obesity to cancer include insulin resistance,
endogenous sex steroids, and adipokines [42]. Accumulating evidence supports that
dietary fat intake is also positively associated with the risk of CRC, PCa, and BrC, but
with much less compelling data for other types of cancers [43-47]. Recently, it has been
recognized that specific types of fats play a much more important role in cancer
development and progression compared to the total amount of fat intake. Particularly,
whereas ω-3 PUFAs, including ALA, EPA, and DHA, are precursors for antiinflammatory mediators, ω-6 PUFAs, including LA and AA are precursors for proinflammatory mediators [23]. The ratio between ω-6 and ω-3 PUFAs is generally
believed to positively correlate with cancer risk [48-50]. A positive correlation between
serum TG levels and the risk of cancers, including lung, colorectal, thyroid, prostate,
breast, endometrial, and gynaecological cancers, has also been reported [51-55], although
there are still some inconsistency among different studies [56-58].

1.1.2

Intracellular Fatty Acid Metabolism and Cancer

Most normal cells acquire lipids from exogenous supplies either in the form of
FFAs or in the form of LDLs [59]. These exogenous lipids derive from both dietary fat
intake and the lipids synthesized in the liver or adipose tissue. De novo fatty acid
synthesis mainly occurs in the liver, adipose tissue, and lactating breast [59]. The TCA
cycle, fueled by both glycolysis and glutaminolysis, produces citrate, which is converted
into acetyl-CoA by ACLY. Acetyl-CoA is then catalyzed by ACC to produce malonylCoA, which is together with acetyl-CoA catalyzed by the critical enzyme FASN to
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generate saturated fatty acid, palmitic acid [60]. Saturated fatty acids can be further
elongated through catalyzation by enzymes ELOVLs. Fatty acyl-CoA desaturases,
including SCDs, can introduce one double bond to produce mono-unsaturated fatty acids
[60]. Because essential PUFAs cannot be synthesized de novo, highly unsaturated fatty
acids are produced by desaturation of essential PUFAs obtained exogenously [60].
1.1.2.1 De Novo Fatty Acid Synthesis in Cancer Cells
Cancer cells adopt metabolic pathways that differ from their normal counterparts
by high rates of de novo fatty acid synthesis to fuel rapid growth. The important role of
de novo lipid synthesis in cancer cell biology has not been recognized until 1990s, when
oncogenic antigen-519 (OA-519), later known as FASN, was found in cancer cells from
BrC patients with poor prognosis [61]. Since then, upregulation of several lipogenic
enzymes in cancer cells has been reported [21, 62] (Figure 1.1). ACLY has been shown
to be important for cell transformation, proliferation and survival in vitro and
tumorigenesis in vivo [63, 64]. ACC has also been reported to be overexpressed in BrC
[65] and crucial for PCa cell growth and survival [66]. FASN, which catalyses the
terminal steps of de novo fatty acid synthesis, represents the most frequently altered
lipogenic enzyme in cancer cells [62]. Upregulation of FASN has been shown in many
types of human cancers and their pre-neoplasia lesions, including breast, prostate, lung,
oral, colorectum, ovary, oesophagus, melanoma, etc [62].
Two major mechanisms have been proposed to account for FASN overexpression
in cancer cells. The major one is through GFs and GFRs. Phosphorylation of GFRs, such
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Figure 1.1 Regulation of lipid metabolism by oncogenic signalling pathways.
Many cancer cells show high rates of de novo lipid synthesis. Fatty acids are
required for the production of phosphoglycerides, which, together with
cholesterol, can be used for building cell membranes. Triacylglycerides and
cholesterylesters are stored in LDs. Lipids from extracellular sources can also
be used for these purposes. Fatty acids mobilized from lipid stores can be
degraded in the mitochondria through b-oxidation to provide energy when
required. Many enzymes within the fatty-acid and cholesterol-biosynthesis
pathways are regulated by SREBPs (highlighted by yellow boxes). Oncogenic
activation of the PI3K/Akt pathway promotes glucose uptake and its use in
lipid synthesis through activation of SREBP. Activation of E2F following loss
of the retinoblastoma protein increases expression of SREBPs and their target
genes. Mutant p53 (p53mut) increases the expression of genes within the
cholesterol biosynthesis (mevalonate) pathway by binding to their promoters.
AMPK is activated in response to low cellular energy levels and prevents lipid
synthesis and stimulates b-oxidation through inhibition of ACC. AMPK can
also inhibit SREBP by direct phosphorylation. Activation of HIF1 by hypoxia
reduces the flux of glucose to acetyl-CoA through the mitochondria.
Reductive metabolism of glutamine-derived a-ketoglutarate provides
cytoplasmic citrate in hypoxic cells. Reprinted with permission from [21].
Copyright © 1999-2013 John Wiley & Sons, Inc.
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as EGFR (also known as ERBB1) and ERBB2 (also known as HER2), activates the
downstream signaling pathways, including PI3K–AKT and MAPK-ERKs (ERK1 and
ERK2) transduction cascades [62] (Figure 1.1). Another possible mechanism is through
steroid hormones, including estrogen, progestin, and androgen, and their corresponding
receptors, i.e. ER, PR, and AR. The binding of steroid hormones to their receptors also
activates the identical downstream pathways [62] (Figure 1.1). Both PI3K-AKT and
MAPK-ERK pathways have been found upregulated and implicated in cancer
pathogenesis [67, 68]. These two oncogenic signaling pathways regulate FASN
expression through SREBPs [69] (Figure 1.1). The SREBPs are transcription factors that
function to control lipid and cholesterol homeostasis by sensing cellular cholesterol [70].
Activation of SREBP has been frequently observed in a number of cancers. The three
SREBP isoforms, SREBP-1a, -1c, and -2, have different roles in lipid synthesis. Whereas
SREBP-1a and -2 are relatively specific to cholesterol synthesis, SREBP-1c is
responsible for de novo fatty acid synthesis [71].
Increased de novo fatty acid synthesis renders new therapeutic targets for cancer
treatment [21, 72]. Among all the overexpressed lipogenic enzymes, FASN is the most
attractive target due to its universal upregulation in various types of cancers [62]. Several
FASN inhibitors have been developed, including C75, orlistat and GSK837149A, and the
current data suggest the potential of FASN to be a good clinical target [62]. Nevertheless,
the side effect of FASN inhibition on central nervous system raises significant concerns
about safety of these drugs [62].
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1.1.2.2 Lipid Hydrolysis in Cancer Cells
The majority of research on altered lipid metabolism in cancer has been focusing
on de novo fatty acid synthesis until the recent finding of MAGL, a lipolytic enzyme that
is highly elevated in aggressive cancer cells from multiple tissues of origin [73, 74]
(Figure 1.1). MAGL hydrolyzes monoacylglycerols to release FFAs, which were found
to correlate with aggressiveness of cancer cells [73, 74]. MAGL inhibition by inhibitor
JZL184 or shRNA was shown to significantly suppress cancer cell proliferation,
migration, invasion, and growth in vivo [73, 74]. Nevertheless, the inhibitory effect of
MAGL inhibition on cancer growth was restored by high-fat diet [73]. Further studies are
needed to clarify whether the functions of fatty acids derived from de novo synthesis or
released from lipolysis are different. This may address the concern about simultaneous
increase of both lipogenesis and lipolysis.
1.1.2.3 FFAs Promote Cancer Development
FFAs have been shown to promote different aspects of cancer development [21,
72] (Figure 1.1). First, quite a number of FFAs are esterified to phospholipids, which are
important structural lipids for membrane synthesis. Second, FFAs are oxidized during
periods of energy stress. As an example, PCa generally displays low levels of glycolysis
and high levels of β-oxidation enzymes [75]. Increased β-oxidation has also been found
in pancreatic cancer, leukaemia, and glioblastoma cells [21, 72]. Third, FFAs provide
sources for derivative signaling lipids, such as phosphatidic acid, lysophosphatidic acid,
prostaglandins, and leukotrienes. Lysophosphatidic acids promote cell aggressiveness
through regulation of G protein-coupled receptors [76]. Both prostaglandins and
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leukotrienes have been implicated in a variety of human malignancies, including
inflammation and carcinogenesis [77]. In addition, FFAs also contribute to other aspects
of cancer biology, such as redox homeostasis and resistance to oxidative stress [21, 72].
1.1.2.4 Neutral Fat Storage in Cancer Cells
Neutral fat are stored in LDs, an organelle that has a monolayer of phospholipid
and specific proteins [22]. Cells contain various types of LDs with distinct functions due
to the proteins attached, such as LD structural proteins, lipid synthesis enzymes, lipases,
and membrane-trafficking proteins. LDs often play dynamic roles in various aspects of
lipid metabolism [78-80]. The aberrant accumulation of LDs is associated with some of
the most widespread human diseases, such as obesity, diabetes type II, and
atherosclerosis [81].
Based on the findings of upregulated expressions of both lipogenic and lipolytic
enzymes, it is conceivable that cancer cells require reservoirs for lipids, namely LDs, to
store newly synthesized lipids on one hand and provide lipids for hydrolysis on the other
hand. Indeed, as early as the 1970s, LDs were reported in clinical studies of mammary
carcinoma [82]. Since then, lipid accumulation has been described in many types of
human cancers, including breast, brain, colon and others [83-85]. For CRC, LDs were
found to serve as reservoirs of cyclooxygenase 2 and prostaglandin synthase [84], which
have been shown to be implicated in various human malignancies including inflammation
and cancer [86]. For PCa, LD accumulation in LNCaP-LP was reported and attributed to
the upregulation of fatty acid synthase [87, 88]. Lipid accumulation was also shown to
contribute to dendritic cell dysfunction in cancer [89]. Despite these scientific progress
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[90], lipid accumulation has not, to date, been used as a prognostic factor or
therapeutic target of cancer. In particular, because compositions of LDs are not
readily accessible with traditional methods, the exact role of lipid accumulation in
cancer progression remains elusive.

1.2

Cholesterol and Cancer

Cholesterol is an essential biomolecule that plays important roles in the
maintenance of membrane structure, signal transduction, and provision of precursor to
hormone synthesis [91]. Although there has been an undoubted link between cholesterol
and cardiovascular disease [92], the role of cholesterol in cancer remains elusive. This
key section will thoroughly review the current understanding of cholesterol metabolism
in cancer at both whole-body and cellular levels.

1.2.1

Whole-body Cholesterol Metabolism and Cancer

Cholesterol can be acquired from diet or endogenous biosynthesis. Dietary
cholesterol is absorbed by enterocytes of the small intestine and is further packaged into
the lipoprotein chylomicrons, which after addition of new apoproteins are taken up by
hepatocytes of the liver [93]. Along with the cholesterol synthesized de novo by the liver,
hepatocytes secrete cholesterol in VLDL particles that are further processed into LDL [59,
93]. LDLs contain the most cholesterol content among all lipoproteins and deliver
cholesterol into periphery tissues for key biological processes. Excess cholesterol from
periphery tissues are released to HDLs, which carry cholesterol back to the liver [59, 93].
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1.2.1.1 Dietary Cholesterol Intake and Cancer Risk
Dietary Healthy dietary pattern (e.g. low in red meat, high in vegetable) has been
recommended to prevent cancer [94]. In order to determine the contribution of dietary
cholesterol intake to cancer risk, a number of epidemiological studies have been
conducted. By evaluating food frequency questionnaire, one study has reported that
dietary cholesterol intake is associated with increased risk of various types of cancers,
including lung, breast, colon, rectum, stomach, pancreas, kidney, and bladder cancers
[95]. A population-based case-control study from Japan also concluded that diet rich in
cholesterol increased pancreatic cancer risk [96]. In contrast, a cohort study of US
women did not support the association between cholesterol intake and pancreatic cancer
risk [97]. In terms of CRC, a number of studies consistently show that dietary cholesterol
significantly increases the risk of CRC [98-100]. Animal study has also shown that
dietary cholesterol is a potent dietary co-carcinogen that promotes carcinogenesis of CRC
in rats [101, 102], and reduced intake of cholesterol suppresses CRC metastasis and
prolongs survival in the rat model [103]. For the squamous and small cell lung cancer
patients who smoke tobacco heavily in Hawaii, cholesterol intake was found to increase
the risk of lung cancer [104]. Another study from Hawaii also supports the role of dietary
cholesterol intake in lung cancer in men but not in women [105, 106]. However, in the
studies conducted among Japanese men in Hawaii and Finnish men, no association was
observed between cholesterol and lung cancer risk [107, 108]. A pooled analysis of 12
cohort studies did not find a correlation between cholesterol or egg intake and the risk of
OvC [109]. Dietary cholesterol did not significantly contribute to mammary tumor
development in rats [110]. Taken together, the link between dietary cholesterol and
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cancer may exist, but it might depend on cancer types. More systematic clinical and
preclinical studies are needed.

1.2.1.2 Blood Cholesterol Levels and Cancer Risk
Based on the large prospective study on cholesterol and cancer conducted in
Korea, the relationship between total-C levels and cancer has varied greatly by tissue of
origin [111]. Whereas total-C levels were positively associated with the risk of BrC, PCa,
and CRC, total-C levels were negatively correlated with the risk of cancers arising from
liver, lung, stomach, and esophageal [111]. A few other studies also suggest that cancer
patients have declined levels of cholesterol in the blood [112-115]. The cholesterol
fraction associated with the decrease in circulating cholesterol was majorly HDL-C [116].
The decreased level of HDL-C has been found to be restored when cancer is in the
remission stage [117]. Because the association between circulating cholesterol levels and
cancer risk varies by cancer types, we will review in more details for the most heavily
studied cancer types as below.
PCa is certainly the most extensively studied cancer type with respect to the
effects of circulating cholesterol levels. A number of prospective studies show that men
with low circulating cholesterol are at lower risk of developing high-grade PCa (Gleason
score 8-10) compared to those with high cholesterol levels. No correlation between
circulating cholesterol levels and the risk of overall or low-grade PCa (Gleason score 2-6)
was found [118-120]. Consistently, men with high cholesterol levels (≥ 240 mg/dL) had
significantly higher risk of high-grade PCa compared to those with low cholesterol levels
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(< 200 mg/dL) [121]. Although there was one study that did not find association between
cholesterol levels and PCa [122], its follow-up study concluded that HDL-C levels were
inversely associated with PCa risk [123]. It was also observed that both total-C/HDL-C
and LDL-C/HDL-C ratios were associated with increased risk of PCa [123]. High HDLC levels were also found to prevent against PCa in another study [124]. All these
epidemiological evidence supports the positive association between hypercholesterolemia
and risk of aggressive PCa.
Preclinical studies also support the role of cholesterol in PCa incidence and
progression. Zhuang et al. [125] and Mostaghel et al. [126] both demonstrated that
elevation of circulating cholesterol in nude mice promoted tumor growth, by increasing
either the phosphorylation of AKT (a key kinase in PCa survival and growth) or the
intratumoral de novo steroidogenesis. Solomon et al. [127] showed that the
pharmacological reduction of serum cholesterol levels hindered human PCa growth in a
mouse xenograft model. Spontaneous PCa models (e.g. TRAMP) have also been used to
strengthen the conclusion that hypercholesterolemia results in enhanced tumor
progression and metastases to the lung [128].
BrC has higher incidence in western countries, which leads to a focus on the link
between diet and BrC risk. Although dietary fat intake affects blood cholesterol levels, it
is not conclusive that blood cholesterol levels contribute to the overall BrC risk. In the
Nurses' Health Study, serum cholesterol levels were not substantially associated with BrC
risk [129]. In a prospective study of postmenopausal women conducted in Korea, a
positive correlation between serum cholesterol levels and BrC incidence was found, but
the strength of the association was significantly reduced after the adjustment for BMI
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[130]. In another study conducted in Sweden, high cholesterol levels were found to be a
risk factor for postmenopausal women but not for premenopausal women [131].
Circulating cholesterol also affects clinical outcome of BrC. A prospective study of
Canadian women reported a high recurrence rate in women with high cholesterol levels
[132]. Another study of Norwegian women shows an increased death from BrC in
women who were in the highest quartile of cholesterol levels [133]. It was also found that
postmenopausal BrC patients had higher oxLDL, total-C, and LDL-C levels compared to
the matched healthy women [134]. The results from epidemiological studies are still not
conclusive, because different BMI or BrC sub-type results in different circulating
cholesterol.
Fewer studies have been performed on the link between cholesterol and other
types of cancer. For OvC, late-stage patients who had normal LDL-C survived
significantly longer than those who had elevated LDL-C [135]. Higher oxLDL levels
were also found in women with OvC compared to the matched control group [134]. In
terms of CRC, a prospective study conducted in Europe found a negative trend for HDLC with CRC, but no significant trend for total-C or LDL-C with CRC [136]. The Japan
Collaborative Cohort Study did not find an association between total-C and CRC neither
[137], even though oxLDL was significantly higher in CRC patients. Nevertheless, higher
levels of total-C, LDL-C and LDL/HDL ratios were observed in CRC patients with
metastases compared to those without metastases [138].
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1.2.1.3 Statin Use and Cancer Risk
As blood cholesterol levels have been shown to be closely correlated with cancer
risk, it is conceivable that cholesterol-lowering drugs may prevent cancer development.
Indeed use of statins, HMGCR inhibitors that lower blood cholesterol levels via blocking
cholesterol synthesis in the liver, has been found to reduce the risk of cancer incidence
and mortality [139-141].
PCa is certainly the most extensively studied cancer type for the effect of statins
on cancer risk [142, 143]. Although there have been some conflicting results, with one
study showing no association [144] and two studies reporting a positive association
between statin use and PCa risk [145, 146], many more studies have collectively support
a protective effect of statins [143]. In 2006, a large prospective cohort study of US male
health professionals, for the first time, demonstrated a protective effect of statins on the
risk of advanced PCa [147]. Specifically, although no association between statin use and
risk of PCa overall was found, current use of statins was shown to reduce risk of
advanced PCa by 49% and of metastatic or fatal PCa by 61%, compared with no current
use. Longer use of statins (≥ 5 years) was associated with even lower risk of advanced
disease (0.26, 95% CI = 0.08 to 0.83). One year later, the California Men's Health Study
showed that long-term use (≥ 5 years) of statins was associated with a 28% lower risk for
PCa compared to nonuse, among regular nonsteroidal anti-inflammatory drug users [148].
According to a large U.S. cohort study (Cancer Prevention Study II Nutrition Cohort),
long-term use (≥ 5 years) of statins was also found to reduce the risk of advanced PCa,
even though not associated with overall PCa incidence [144, 149]. A population-based
case-control study conducted in Finland further supported that users of statins, including
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atorvastatin, lovastatin, and simvastatin, had significantly lower risk of developing
advanced PCa [150]. Recently, more reports have shown the positive correlation between
statin use and reduced risk of high-grade PCa [151, 152]. Based on the data in Veterans
Affairs New England Healthcare System, statin users were 31% less likely to be
diagnosed with PCa and 60% less likely to be diagnosed with high-grade PCa, compared
with antihypertensive medication users [153]. Studies also found that statin users were
less likely to have high PSA levels [154] or develop high-grade PIN [155]. Statin use was
associated with a significant improvement in PSA relapse-free survival in high-risk
patients who received radiotherapy [156], and reduced risk of recurrence after
prostatectomy [157] and death from PCa [158]. Collectively, these studies strongly
support the hypothesis that statins reduce the risk of advanced PCa.
A number of clinical trials have been conducted to evaluate the effect of statins on
BrC risk. The majority of earlier studies did not find an association between statin use
and BrC risk [159]. Several recent epidemiologic studies showed promising results of
statin use in BrC prevention [160-162]. The reason for this inconsistency is possibly that
earlier studies analyzed all statin users as a single group, whereas the recent studies
compared clinical outcomes for different types of statins (e.g. hydrophilic, hydrophobic)
[163]. One of the most recent study, Danish Nationwide Prospective Cohort Study),
showed that use of hydrophobic statins reduced both incidence and recurrence of BrC
over 10-year follow-up [160]. Other two studies also supported the protective effect of
hydrophobic statins on BrC incidence [162] and recurrence [161]. A recent cohort study
on primary inflammatory BrC showed that lipophilic statins significantly improved
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progression-free survival [164]. A prospective randomised study evaluating the benefits
of certain types of statins in BrC is warranted.
Fewer studies have been performed to evaluation the association between statin
use and the risk of other types of cancer. There was one earlier study reporting 47%
reduction in CRC incidence associated with long-term use of stains [165]. Unfortunately,
later studies with mixed results could not reproduce this finding [166]. A 55% reduction
in the incidence of lung cancer was found in statin users [167]. However, this finding was
argued to be misleading due to a failure of correcting immortal time bias [168]. For OvC,
statin use was found to be associated with longer progression-free and overall survival in
women diagnosed with stage III/IV OvC [169].
The mechanism by which statins prevent cancer is an intense area of research.
Statins are inhibitors of HMGCR, thus blocking the entire mevalonate pathway. As a
result, not only cholesterol synthesis but also other cholesterol-independent reactions,
including G-protein posttranslational modification, are inhibited by statins [139]. Gprotein (e.g. Ras, Rac, and Rho) posttranslational modification has been shown to
enhance many oncogenic events including cell proliferation and metastatic potential
[139]. Nevertheless, it has been proposed that the protective effect of statins on cancer in
vivo is largely attributed from their cholesterol-lowering capabilities [140, 143] instead of
the local effects on cancer cells.

1.2.2

Intracellular Cholesterol Metabolism and Cancer

Inside cells, cholesterol is an essential molecule that plays important roles in the
maintenance of membrane structure, signal transduction, and provision of precursor to

18
hormone synthesis [93]. Cholesterol can be either de novo synthesized via the mevalonate
pathway or taken up from exogenous lipoproteins LDL [93]. LDL is known to enter a cell
via LDLr and traffic to the late endosome and lysosome to be hydrolyzed to free fatty
acids and free cholesterol. The excess free cholesterol together with the fatty acyl CoA
substrate is converted to CE by ACAT and stored in LDs [170] (Figure 1.2).

Figure 1.2 Intracellular cholesterol regulation. Cholesterol enters cells via LDLrmediated endocytosis. CE in LDL is hydrolyzed to FC and FFAs in late endosome and
lysosome system. Together with cholesterol synthesized de novo in the ER, excess FC is
esterified into CEs and stored in LDs or effluxed to extracellular acceptors, such as HDL.
FC majorly locates on plasma membranes. HSL is used for neutral lipid hydrolysis to
mobile lipids for important signaling pathways.

1.2.2.1 Cholesterol Synthesis, Uptake, and Efflux in Cancer Cells
Whereas synthesis and uptake increase cellular cholesterol levels, efflux reduces
cellular cholesterol levels. HMGCR is the rate-limiting enzyme that catalyzes important
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steps in cholesterol synthesis. A number of studies have shown that HMGCR is
upregulated in many types of cancer cells and HMGCR inhibition leads to growth arrest
and apoptosis [171-174]. With respect to cholesterol uptake, over-expression of LDLR
has been observed in many types of aggressive cancer cells, including metastatic PCa
[175, 176], ER- BrC [177, 178], and glioblastoma [179]. ABCA1 and ABCG1 are the
major regulatory proteins for cholesterol efflux. ABCA1 downregulation was found in
high-grade PCa tissues but not in benign prostate, and expression levels of ABCA1 were
inversely associated with Gleason grades [180].
1.2.2.2 Cholesterol Homeostasis in Cancer Cells
Intracellular cholesterol homeostasis is regulated by two master transcriptional
factors, the SREBP and LXR. The regulation of SREBP activity and the role of SREBP
in cell metabolism have been thoroughly explored [70, 181]. In brief, when cellular
cholesterol levels are low, SREBP gets activated and the cleaved form of SREBP
migrates into nucleus to upregulate target genes, including HMGCR and LDLr, to
promote cholesterol synthesis and uptake. SREBP has three isoforms, SREBP-1a, -1c,
and -2, which play different roles in lipid synthesis. SREBP-1c is responsible for fatty
acid synthesis, whereas SREBP-1a and -2 are relatively specific to cholesterol synthesis
[71]. When cellular cholesterol levels are high, free cholesterol is oxidized to form
oxysterols. The increased levels of oxysterols can be sensed by LXR, which activates
MYLIP/IDOL for LDLr degradation and ABCA1 (or ABCG1) for cholesterol efflux
[182]. Increased activation of SREBPs has been reported in advanced PCa [183] and
glioblastoma [179]. LXR agonists have been shown to induce death of glioblastoma cells
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by reducing cholesterol uptake and increasing cholesterol efflux [179]. LXR agonist has
also been reported to delay the progression of androgen-dependent PCa to androgenindependent PCa after castration [184].
1.2.2.3 Cholesterol as a Precursor of Steroidogenesis in Cancer Cells
Cholesterol is the common precursor of five different classes of steroid hormones.
Steroid hormones are generally believed to be synthesized in specialized organs, the
adrenal glands, testes, and ovaries. Steroid hormones are known to stimulate proliferation
and differentiation of BrC, PCa, and endometrial cancer cells. Hormonal therapy has
become standard therapy for several types of cancers. For men with advanced PCa,
androgen deprivation therapy is an accepted standard therapy. Despite initial disease
control, androgen deprivation therapy alone is non-curative and the subsequent
development of castration-resistant PCa occurs in the lifespan of almost all men who do
not succumb to non-cancer deaths [185]. Increasing evidence supports that androgen
signaling pathways remain transcriptionally active in castration-resistant PCa [185]. The
studies collectively demonstrate that castration-resistant PCa cells have the entire
functional mevalonate-steroidogenesis pathway for de novo DHT synthesis [186-188].
Cholesterol has been shown to promote progression of castration-resistant PCa by
activating the androgen signaling pathway in vivo [189]. These findings suggest that
cholesterol could be a potential target for castration-resistant PCa [190].
1.2.2.4 Cholesterol-rich Membrane Domains (Lipid Raft) in Cancer Cells
The membrane domains rich in sphingolipids and cholesterol are called lipid rafts
[191]. There are two types of lipid rafts: planar lipid rafts and caveolae. Lipid rafts
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function as hubs for the assembly of signaling molecules and cellular signal transduction
[191]. Lipid raft signaling has been shown to be involved in various human pathogenesis,
including cardiovascular disease, neurodegenerative disease, and cancer [192]. The
essential role of cholesterol accumulation within membrane lipid raft in PCa progression
has been thoroughly reviewed [193]. Caveolae are omega-shaped invaginations of the
plasma membrane rich in caveolin protein family, including caveolin-1 [191]. Caveolin-1
has been implicated in cancer development, progression, and metastasis, particularly in
PCa [194, 195]. In some cancer types, such as breast cancer, caveolin-1 may act as a
negative regulator of tumorigenesis [196]. The ambiguous role of caveolin-1 in cancer
may stimulate further research on the role of membrane lipid raft in cancer. A molecular
understanding of the contribution of membrane lipid rafts to cancer development
has assisted the design of effective therapeutic strategies. The utility of membrane
lipid rafts as diagnostic markers of cancer needs further research.
1.2.2.5 Cholesterol Esterification and Storage in Cancer Cells
Increase cholesterol esterification and storage have been reported in leukemia
[197-201], brain cancer [201-203], clear-cell renal carcinoma [201, 204-206], and BrC
[177]. Although CE accumulation in foam cells is known to be a hallmark of
atherosclerosis, its exact clinical and biological role in cancer progression remains
elusive. Further investigation into clinical relevance of CE accumulation in various
types of human cancers would determine whether CE is a potential marker for
cancer diagnosis. Future elucidation of the molecular mechanisms by which CE is
accumulated in cancer cells and how CE accumulation contributes to cancer
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initiation and progression is also warranted for validation of cholesterol
esterification as a potential target for cancer treatment.
In summary, the essential role of cholesterol metabolism in cancer development
and progression has been increasingly recognized [166, 207-211]. Future study along this
direction will open new avenue to cancer diagnosis and treatment.

1.3

Current Analytical Tools for Lipid Research

Conventionally, the investigation of intracellular lipid and its accumulation in
cancer cells relies on nonspecific, invasive, or population-average measurements. Unlike
many proteins where there are specific antibodies, most lipid molecules have no known
specific markers, so fluorescent signals from lipophilic dyes (e.g. ORO for LD staining,
and DiO or DiI for membrane staining) contain no information regarding lipid
composition or organization. Similarly, electron microscopy imaging of intracellular lipid
body lacks compositional information as well.
To analyze the composition of lipids, standard techniques, including mass
spectrometry and NMR spectroscopy, have been employed. Although such analytical
techniques are powerful, they require the most sample preparation and provide only
population-average information without spatial distribution. The recent development of
DESI-MS renders information of both lipid composition and spatial distribution [212],
but the low resolution (~250 μm) hinders its application to cellular studies. Spontaneous
Raman spectroscopy is another powerful analytical method that has been widely used in
biomedical research [213-215]. However, spontaneous Raman signals are too weak to be
used for high-speed imaging of lipids in biological samples.
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One of the major roadblocks that prevent the research of lipids in cancer from
advancing is a lack of suitable tools for charactering intracellular lipids at single cell level
in a heterogeneous tissue context. Cancer tissues are known to comprise not only cancer
cells but also many types of stromal cells, such as fibroblasts and inflammatory cells [15,
216]. Moreover, human cancer tissues are even more complex because they are very
likely to contain both benign and cancerous cells with different histological grades within
the same piece of tissue. Undoubtedly, new methodologies which allow non-invasive,
compositional, and single-cell measurement of lipids in an intact tissue environment
are warranted to advance our understanding of the role of intracellular lipids in
cancer development.

1.4

Label-free Spectroscopic Imaging of Lipids in Single Live Cells

A portion of the work presented in this section was published in Laser &
Photonics Reviews [217]. Reprinted with permission from [217]. Copyright © 1999-2013
John Wiley & Sons, Inc.
An attractive alternative to dye-labeled assay is coherent Raman microscopy,
including CARS microscopy and recently developed SRS microscopy (Figure 1.2). Both
of them are label-free chemical imaging techniques that probe intrinsic molecular
vibrations. CARS is a NLO process in which the interaction of a pump field Ep(p) and a
Stokes field Es(s) with a sample generates an anti-Stokes field Eas at the frequency of
2ps. CARS microscopy is particularly sensitive to lipid-rich structures when the
beating frequency (ps) of the two pulsed lasers is tuned to 2840 cm-1 that matches
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Figure 1.3 Energy diagrams and setup schematic of CARS and SRS
microscopy, and Raman spectroscopy. Solid lines represent electronic and
vibrational states of molecules, dashed lines are virtual states. The straight
arrows are excitation beams, the wavy arrows are output signal beams. The
gray arrows represent relaxation in electronically excited states. ω1 and ω2 are
two beams available in the CARS microscope. ωp = ω1 and ωs = ω2 in CARS
and SRS level diagram. Here SRG is shown as an example for SRS. Ω is a
frequency of vibrational transition between vibrational ground state v = 0 and
vibrationally excited state v = 1. ω1 and ω2 are pump and Stokes beams from
the laser sources, respectively. OM is an optical modulator, SU is a scanning
mirror unit. DM is an exchangeable dichroic mirror. The inset shows the
connections between electronic components for phase-sensitive heterodyne
detection. Lock-in is a lock-in amplifier, PD is a photodiode, PC is a computer,
FG is a function generator. The blue-colored components are used for
modalities with homodyne type of detection. The light blue color represents
components required for modalities with heterodyne detection. The
spectrometer is used for fingerprint spectral analysis.

the symmetric vibration of CH2 bands. Such single-frequency CARS microscopy has
been applied to image cellular membranes, myelin sheath, and intracellular lipids with 3D
and sub-micron spatial resolution [218-222]. Compared to CARS, SRS microscopy offers
two major advantages: (1) SRS signal is free of the nonresonant background, which
makes it highly sensitive; (2) SRS signal is linearly proportional to the molecular
concentration, which facilitates data interpretation and quantification [217]. In
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microscopy, the modulations of pump and Stokes beam intensities due to the SRS process
are usually very small ( I I

10 4 ) as calculated for experimental imaging conditions

[223]. Therefore, modulation of the excitation beam and phase-sensitive detection
method are needed to pick the signal out of the laser noise. High-speed SRS microscopy
has been recently demonstrated [224-229] and applied to vibrational imaging of tablets
and biomass [230, 231]. We have published a detailed review on coherent Raman
microscope and its biological applications (please see Ref. [217]).
In response to the strong demand for a novel technique that can visualize
intracellular lipids with submicron resolution and analyze their composition in situ, we
have developed a vibrational spectromicroscope that integrates coherent Raman
microscopy and spontaneous Raman spectroscopy on the same platform [232]. With the
capability of vibrational imaging and spectral analysis within a few seconds, vibrational
spectromicroscope has been applied to analyze intracellular lipids in live tissues and
obtain important information including lipid amount and size, degree of carbon chain
unsaturation, and lipid-packing density [233]. We expect this label-free spectroscopic
imaging technique to significantly advance the field of lipid metabolism in cancer.

26

CHAPTER 2. ALTERED CHOLESTEROL METABOLISM: NEW AVENUE TO
DIAGNOSIS AND TREATMENT OF HUMAN PROSTATE CANCER

The work presented in this chapter has been submitted to Cell Metabolism.
Altered lipid metabolism is increasingly recognized as a signature of cancer cells.
Enabled by label-free Raman spectromicroscopy, we performed the first quantitative
analysis of lipogenesis at single cell level in human patient cancerous tissues. Our
imaging data revealed an unexpected, aberrant accumulation of esterified cholesterol in
LDs of high-grade PCa and metastases. Biochemical and molecular biological studies
showed that such CE accumulation was a consequence of loss of tumor suppressor PTEN
and subsequent activation of PI3K/AKT pathway in PCa cells. Furthermore, we found
that such accumulation arose from significantly enhanced uptake of exogenous
lipoproteins and required cholesterol esterification. Depletion of CE storage using
pharmacological inhibitors or RNA interference significantly reduced cancer proliferation,
impaired cancer invasion capability, and suppressed tumor growth in mouse xenograft
models with negligible toxicity. These findings open new opportunities for diagnosing
and treating PCa by targeting the altered cholesterol metabolism.
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2.1

Introduction

Cancer cells adopt metabolic pathways that differ from their normal counterparts
by high rates of glycolysis and biosynthesis of essential macromolecules to fuel rapid
growth [8]. Among dysregulated metabolic pathways, increased de novo synthesis of
lipids has become a common characteristic of human cancers [21]. For instance, FASN,
the key enzyme that catalyzes the terminal steps in fatty acid synthesis, is frequently
upregulated in human malignancies and plays important roles in cancer pathogenesis [62,
234]. In parallel with lipogenesis, lipolysis has also been shown to be elevated in multiple
human cancers [73]. Specifically, MAGL, the lipolytic enzyme that hydrolyzes
monoacylglycerols to release FFAs, was found to be overexpressed in aggressive cancer
cells. Based on the findings of upregulated expressions of both lipogenic and lipolytic
enzymes, it is conceivable that cancer cells require reservoirs for lipids, namely LDs, to
store newly synthesized lipids on one hand and provide lipids for hydrolysis on the other
hand. Indeed, as early as the 1970s, LDs were reported in clinical studies of mammary
carcinoma [82]. Since then, lipid accumulation has been described in many types of
human cancers, including breast, brain, colon and others [83-85]. Nonetheless, lipid
accumulation has not, to date, been used as a prognostic factor or therapeutic target of
cancer. In particular, because compositions of LDs are not readily accessible with
traditional methods, the exact role of lipid accumulation in cancer progression remains
elusive.
LDs are visualized mainly through labeling with lipophilic dyes, which requires
fixation and lacks compositional information. To assay for lipid composition, analytical
tools, such as mass spectrometry and nuclear resonance spectroscopy, are commonly

28
used. Because such techniques analyze tissue homogenates, it is impossible to obtain
compositional information of individual LDs inside cells. The recently developed
coherent Raman scattering microscopy [235] has shed new light on the study of LD
biology [217, 236], with its label-free detection capability, high imaging speed, and
submicron spatial resolution. Using this technique, high-speed vibrational imaging of LD
dynamics in live cells and embryos has been demonstrated [237-241]. Multiplex CARS
microscopy has been used to study phase separation in LDs of 3T3-L1 cells [242].
Coupling the high-speed imaging capability of coherent Raman scattering microscopy
and full spectral analysis capability of spontaneous Raman spectroscopy allowed
quantitation of not only the amount, but also the composition, of individual LDs in live
cells [243].
Here, we report the first quantitative analysis of lipogenesis at the single cell level
in intact tissues from a spectrum of human prostate pathologies. Our label-free imaging
study revealed an unexpected accumulation of CE in high-grade and metastatic human
PCa tissues, but not in normal prostate, BPH, prostatitis, or PIN tissues. Our biochemical
study further showed that such CE accumulation was induced by loss of tumor suppressor
PTEN, upregulation of PI3K/AKT/mTOR pathway, and consequent activation of SREBP
and LDLr. Pharmacological inhibition of cholesterol esterification significantly
suppressed cancer proliferation, migration, invasion, and tumor growth in vivo. These
data collectively herald the potential of using CE as a marker for diagnosis of aggressive
PCa and open a new way of treating advanced PCa by targeting the altered cholesterol
metabolism.
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2.2
2.2.1

Experimental Section

Human Prostate Tissue Specimens

This study was approved by institutional review board. Frozen specimens of
human prostate tissues derived from patients who underwent radical prostatectomy for
PCa were obtained from Indiana University Simon Cancer Center Solid Tissue Bank.
These patients had not received hormone therapy before radical prostatectomy. In
addition, frozen specimens of normal prostate tissues donated from healthy subjects and
metastatic PCa tissues collected by warm body autopsy from patients who had failed
hormone therapy were obtained from Johns Hopkins Hospital. Totally, 19 normal
prostates, 10 BPH, 3 prostatitis, 3 PIN lesions, 12 low-grade PCa (Gleason grade 3), 12
high-grade PCa (Gleason grade 4/5), and 9 metastatic PCa [liver (n = 2), lymph node (n =
3), rib (n = 1), lung (n = 1), adrenal (n = 1), and abdominal soft tissue (n = 1)] from 64
different patients or healthy donors were analyzed. For each tissue specimen, pairs of
neighboring slices were prepared, with one slice remained unstained for spectroscopic
imaging and the other stained with H&E. Pathological examination was made by
genitourinary pathologists.
2.2.2

Cell Culture

K-SFM with additives BPE and hEGF, RPMI 1640, T-medium, and FBS were
purchased from Invitrogen. F-12K and EMEM were obtained from ATCC. Cells were
cultured in the following media: RWPE1 in K-SFM supplemented with BPE (0.05 mg/ml)
and hEGF (5 ng/ml). LNCaP-LP, LNCaP-HP, and 22Rv-1 in RPMI 1640 supplemented
with 10% FBS. PC-3 in F-12K supplemented with 10% FBS. DU145 in EMEM
supplemented with 10% FBS. C4-2 in T-medium supplemented with 10% FBS. LNCaP-
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HP was derived upon continuous passage from original LNCaP from ATCC (LNCaP-LP)
until the passage number was over 60, and is an established cell line of AR-positive but
androgen-independent PCa [244-247].
2.2.3

Chemicals

LY294002, MK2206, rapamycin, avasimibe, simvastatin, Sandoz 58-035, DEUP,
cholesteryl oleate, glyceryl trioleate, A922500, DHT, and AA were purchased from
Sigma-Aldrich. Human LDL was obtained from Creative Laboratory Products. LPDS
was purchased from Biomedical Technologies. The PTEN inhibitor BPV(pic) was
purchased from Enzo Life Sciences.
2.2.4 Label-free Spectroscopic Imaging
Label-free spectroscopic imaging was performed on unfixed and unstained tissue
slices (~ 20 µm) and live cells without any processing or labeling. SRL imaging was
performed on a femtosecond SRL microscope, with the laser beating frequency tuned to
the C-H stretching vibration band at 2845 cm-1, as described previously [248].
Compositional analysis of individual LDs and autofluorescent granules was performed by
integration of high speed CARS imaging and confocal Raman spectral analysis on a
single platform [243]. We quantify lipid metabolism profiles in two aspects, that is, LD
amount (or LD area fraction) and CE percentage. By using ImageJ “Threshold” function,
LDs in the cells can be selected because of their significantly higher signal intensities
compared to other cellular compartments. Then, by using ImageJ “Analyze Particles”
function, area fraction of LDs out of total image area can be quantified. For tissue
specimen, the area fractions of LDs from the two different locations were averaged to
obtain the final value of LD area fraction. For cultured cells, the area fraction of LDs was
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normalized by cell number to obtain LD amount, and 50~100 cells were analyzed. The
percentage of CE in individual LDs was quantified by using the equation, that is, Height
ratio (the height ratio of the 702 cm-1 peak to the 1442 cm-1 peak, I702/I1442) = 0.00255 ×
CE percentage (%). The corresponding calibration curve is shown in Figure 2.2T. For
statistical analysis, CE percentage for each specimen or cell culture was obtained by
averaging the CE percentage of LDs in 5~10 cells, given that Raman profiles of LDs in
different cells in the same specimen or cell culture were nearly the same (Figure 2.2R).
Average acquisition time for a 512 x 512 pixels SRL image was 1.12 second.
Large-area SRL imaging was performed on a motorized stage. Each large-area SRL
image was generated by stitching 100 images of ~157 µm × 157 µm in size together. Two
different locations were imaged for each specimen. Simultaneously, backward-detected
two-photon fluorescence signal was collected through a 520/40 nm bandpass filter for the
imaging of autofluorescent granules.
The background of Raman spectrum was removed as described [243]. 5-10
spectra of LDs or autofluorescent granules in 5-10 different cells were taken for each
specimen. Each Raman spectrum ranged from 380 to 3100 cm-1 and was acquired in 20
seconds. The laser (~707 nm) power at the specimen was maintained at 15 mW, and no
cell or tissue damage was observed.
2.2.5

Fluorescence Imaging of LDL Uptake

DiI-LDL was made using dry film method [249]. Cells in growth medium
containing 10% lipoprotein deficient serum with or without the indicated inhibitors (for
2d) were incubated with DiI-LDL (20 µg/ml) for 3 hr at 37 °C and then imaged by twophoton fluorescence microscopy through a 600/60 nm bandpass filter. The LDL uptake
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was quantified based on fluorescence intensity of DiI using ImageJ, and normalized by
cell number. No LDL uptake was detected in cells incubated at 4 °C.
2.2.6

Cell Viability Assay

Cells were grown in 96-well plates (~5000 cells/well) and cultured for 1 day
followed by indicated treatments. Cell viability was measured with the MTT colorimetric
assay (Sigma). IC50 was obtained by fitting the data with sigmoidal dose response model.
2.2.7

Cell Cycle Analysis

PC-3 cells treated with 7.5 µM avasimibe for 3 days and the untreated ones were
collected, fixed, and stained with 50 µg/ml PI at 37 °C for 30 min. The DNA content was
measured by Cytomics FC500 flow cytometer (Beckman Coulter). Data were processed
and analyzed by FlowJo software (Tree Star). Cell-cycle phases and frequencies of each
phase were determined by fitting the data with Watson-Pragmatic model.
2.2.8

Migration and Invasion Assays

Invasion and migration assays were performed in Transwell chambers (Corning)
with 8 µm pore-sized membranes, coated with and without Matrigel (BD Bioscience)
respectively. One to two days before the start of the assays, cells received indicated
treatments. At the start of the assays, cells were harvested and counted. 1×106 cells were
seeded in the upper chamber of the transwells in 1.5 ml serum-free media. The media in
lower chamber contain 20% FBS. Cells were allowed to migrate for 12 hr and invade for
24 hr at 37 °C. The transwell membranes were then fixed and stained with PI. Cells that
had not migrated or invaded through the chamber were removed with a cotton swab. The
cells that migrated or invaded were imaged by two-photon fluorescence microscopy, and
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4 fields were independently counted from each migration or invasion chamber. An
average of cells in 4 fields for one migration or invasion chamber represents n = 1.
2.2.9

ESI-MS Measurement of Lipid Extraction

Lipid extraction from cell pellets and tissues was performed according to Folch et
al [250]. Cells with indicated treatments were collected and counted. ESI-MS analysis
was conducted according to the protocol described previously [251]. The relative level of
cholesteryl oleate (18:1) was normalized by cell number for comparison between control
and avasimibe-treated cells, and was normalized by tissue weight for comparison
between normal prostate and PCa tissues.
2.2.10 Biochemical Measurement of Cellular Lipids
Lipids were extracted as described above. CE, free cholesterol, and TG
concentrations were measured according to the manufacturer’s protocol (Amplex Red
Cholesterol kit from Molecular Probes, Serum Triglyceride Determination Kit from
Sigma), and finally normalized by protein content that was determined by bicinchoninic
acid assay.
2.2.11 LC-MS Analysis of AA
Cells cultured in 10% LPDS were pre-treated with 7.5 µM avasimibe for 2 days
or transfected with ACAT-1 shRNA for 3 days. LDL (20 µg/ml) were then added back to
the medium for 6 hr before the cells were collected and counted. Fatty acids were
extracted and measured according to the methods described previously [252]. The final
AA concentration was normalized by cell number.
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2.2.12 Immunoblotting
After indicated treatments, cells were lysed in AMI lysis buffer (Active Motif),
and proteins were detected by immunoblotting with the antibodies against SREBP-1 (BD
Pharmingen, 557036), SREBP-2 (Santa Cruz, sc-5603), p-AKT (Cell Signaling, 4060L),
p-S6 (Cell Signaling, 2211L), LDLr (Millipore, MABS26), ACAT-1 (Santa Cruz, sc69836), and β-actin (Sigma, A5441).
2.2.13 IHC
Murine paraffin-embedded slides were deparaffinized and rehydrated. Then
antigens were retrieved in antigen unmasking solution (Vector Laboratories) with a 2100Retriever (PickCell Laboratories). Samples were then incubated with the antibody against
Ki67 (Abcam, ab16667) or subjected to TUNEL assay (Roche, 11684817910).
2.2.14 RNA Interference
RNA interference was employed to specifically deplete endogenous SREBP-1,
SREBP-2, ACAT-1, and PTEN. Plasmids pLKO.1-SREBP-1 and pLKO.1-SREBP-2
were constructed with the targeting sequences CAACCAAGACAGUGACUUCCC and
CAACAGACGGUAAUGAUCACG. The ACAT-1 shRNA plasmid and PTEN shRNA
lentiviral particle were purchased from Santa Cruz (sc-29624-SH, sc-29459-V). Plasmid
DNA was transfected with Lipofectamine®2000 (Invitrogen 11668030) as described in
the manufacturer’s protocols.
2.2.15 Treatment of PCa in a Mouse Xenograft Model
The protocol for this animal study was approved by the Purdue Animal Care and
Use Committee. PC-3 cells (2 × 106) were mixed with an equal volume of Matrigel (BD
Bioscience) and inoculated subcutaneously into the right flank of 6-week-old athymic
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nude mice (Harlan Laboratories). Treatments started 2 weeks after tumor implantation
when the xenografts were about ~100 mm3 (day 0). Inhibitors were dissolved in DMSO,
diluted with the solvent PBS containing 1% Tween-80, and administrated via daily
intraperitoneal injections for 30 days at the dose of 15 mg/kg for avasimibe and Sandoz
58-035, and at the dose of 3 mg/kg for A922500. The reason that the dosage of A922500
is lower than that of Sandoz 58-035 and avasimibe is A922500 has substantially lower
IC50 compared to Sandoz 58-035 or avasimibe for inhibition of the target enzyme, that is,
IC50 of A922500 to inhibit DGAT-1 is ~7 nM vs. IC50 of Sandoz 58-035 and avasimibe
is ~3.3 µM [253-255]. Thus, the dosages for injections were selected based on previous
animal studies on these inhibitors [253, 256, 257]. Tumor volume, estimated from the
formula: V=L×W2/2 (V: volume, mm3; L: length, mm; W: width, mm), was measured
twice a week with digital calipers. Relative tumor volume = tumor volume / initial tumor
volume (measured on day 0), for each mouse. Body weight was also measured twice a
week. Tumors and major organs, including heart, liver, lung, kidney, and spleen, were
harvested on day 30 and prepared for tumor weight measurement, spectroscopic imaging,
H&E, and IHC staining.
2.2.16 Statistical Analysis
Results of LD area fraction and CE percentage in human prostate tissues were
shown as mean ± SD. Other results were shown as mean ± SEM. One-way ANOVA was
used for comparisons of LD area fraction, LD amount, and CE percentage among
different lesion types of human PCa and different treatment conditions of cell cultures.
All other comparisons that only include two groups in cellular and animal studies were
performed using the Student’s t test. p < 0.05 was considered statistically significant.
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2.3
2.3.1

Results

Aberrant Accumulation of Esterified Cholesterol in Advanced Human PCa
Revealed by Raman Spectromicroscopy

We examined a spectrum of human prostate pathologies, including normal
prostate from healthy donors and normal adjacent tissues from PCa patients (n = 19),
BPH (n = 10), prostatitis (n = 3), PIN (n = 3), low-grade (Gleason grade 3, n = 12) and
high-grade (Gleason grade 4/5, n = 12) PCa from patients who had not received hormone
therapy, and metastases (n = 9) from patients who had failed hormone therapy. By tuning
the laser beating frequency to be resonant with C-H stretching vibration, substantial SRL
signals arose from the lipid-rich cell membranes and intracellular LDs, whereas weak
SRL signals were derived from the lipid-poor cell nuclei. Morphologically, the SRL
images provided identical information as H&E-stained slides. In normal prostate, BPH,
PIN, and prostatitis, single layers of epithelial cells facing large lumens were identified
by SRL imaging (Figures 2.1A, 2.2). In cancerous specimens, the SRL signals revealed
small glandular structures in low-grade PCa (Figure 2.1B) and cell clusters or sheets
without any glandular structures in high-grade PCa (Figure 2.1C). SRL image of
metastasis is shown in Figure 2.1D. All diagnoses were confirmed by pathologic
assessment of the neighboring slices stained with H&E (Figures 2.1E-H, 2.2). By
combining SRL with two-photon fluorescence on the same microscope, we found that the
intracellular granules present in normal prostate expressed both SRL and fluorescence
signal (Figure 2.1I), which peaked at 520 nm (Figure 2.2M).
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Figure 2.1 Aberrant CE accumulation in human PCa tissues. (A-D) Large-area
SRL images and benign prostate, low-grade PCa (Gleason grade 3), highgrade PCa (Gleason grade 4), and metastatic PCa (liver), respectively. (E-H)
Corresponding hematoxylin and eosin (H&E) staining of adjacent slices.
Scalar bar, 100 µm. (I-L) High magnification SRL and two-photon
fluorescence images of the lesions shown in (A-D) (grey: SRL, green: twophoton fluorescence). Autofluorescent granules and LDs indicated by red
arrows. Scalar bar, 20 µm. (M) LD area fraction in 58 specimens: normal
prostate (n = 19), low-grade PCa (n = 9), high-grade PCa (n = 11), and
metastatic PCa (n = 9). Mean of LD area fraction indicated by red line. n.s.
means not significant. (N) Raman spectra of autofluorescent granules in
normal prostate, LDs in PCa, and pure cholesteryl oleate. Spectral intensity
was normalized by CH2 bending band at 1442 cm-1. Black arrows indicate the
bands of cholesterol rings at 702 cm-1. (O) CE molar percentage in LDs of
low-grade PCa (n = 9), high-grade PCa (n = 11), and metastatic PCa (n = 9).
Error bars represent SD.
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These autofluorescent granules were consistently seen in all 19 normal prostates, 10 BPH,
and 3 PIN lesions (Table 2.1, Figure 2.2G-I), and were determined to be lipofuscin
according to previous reports on pigments in benign prostate [258]. No LDs or
autofluorescent granules were observed in prostatitis specimens (Figure 2.2J-L). In
contrast, with the exception of 4 borderline PCa cases, the 20 primary PCa and all 9
metastases contained significant amount of LDs but no autofluorescent granules (Figure
2.1J-L, Table 2.1). Interestingly, we have found in a spontaneous mouse model of PCa
(TRAMP) that whereas normal mouse prostate only contains autofluorescent granules,
cancerous mouse prostate show accumulation of neutral LDs (Figure 2.2N-O). By largearea mapping and quantitation, the area fraction of LDs in human PCa tissues was found
to be 0.78 ± 0.65% for low-grade PCa, 3.93 ± 1.74% for high-grade PCa, and 2.76 ± 1.19%
for metastatic PCa (Figure 2.1M, Table 2.1). The high-grade PCa has significantly higher
LD area fraction by ~5 folds (p = 8.9E-5) compared to low-grade PCa.
To evaluate the lipid composition, we performed confocal Raman spectral
analysis of individual autofluorescent granules or LDs accumulated in each lesion type.
Figure 2.1N shows representative spectra collected from normal prostate, low-grade PCa
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Figure 2.2 CE accumulation in normal prostate, BPH, PIN, or prostatitis. (A-I)
Label-free SRL and two-photon fluorescence imaging of normal prostate,
BPH, and PIN. (J-L) Label-free SRL and two-photon fluorescence imaging of
prostatitis tissue. Grey: SRL; Green: two-photon fluorescence. Scalar bar: 100
µm for large-area images, 20 µm for high-magnification images. (M)
Normalized two-photon fluorescence spectrum of autofluorescent granule in
normal prostate. (N-O) SRL and two-photon fluorescence images of normal
and cancerous mouse prostate tissues in a spontaneous PCa TRAMP model.
Scalar bar, 20 µm. (P) Raman spectra of different autofluorescent granules in
one normal prostate tissue. (Q) Raman spectra of autofluorescent granules in
BPH and PIN lesion. (R) Raman spectra of LDs in different cells in one PCa
specimen. (S) Raman spectra of CE-TG emulsions with eight different CE:TG
molar ratios, ranging from 0:10 to 10:0. (T) Calibration curve for
quantification of CE percentage out of total neutral lipid. (U) Mass spectra of
lipids extracted from normal prostate and high-grade PCa tissues.
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(Gleason grade 3), high-grade PCa (Gleason grade 4), metastatic PCa (liver), and pure
cholesteryl oleate. The autofluorescent granules seen in normal prostate consistently
showed readily detectable bands for lipid (1200-1800 cm-1), phenylalanine (~1000 cm-1),
and prominent CH3 stretching (~2930 cm-1), but lacked the characteristic C=O ester
stretching band at 1742 cm-1 (Figure 2.2P). These data suggest that the autofluorescent
granules are primarily composed of unesterified lipids and proteins. Similar Raman
profiles were seen in both BPH and PIN lesion (Figure 2.2Q). Importantly, the spectra of
intracellular LDs in low-grade, high-grade, and metastatic PCa (Figure 2.1N) were
distinctly different from those collected in normal prostate, BPH, and PIN lesions, but
nearly identical to the spectrum of pure cholesteryl oleate, with characteristic bands at
428, 538, 614 and 702 cm-1 for cholesterol ring and for ester bond at 1742 cm-1 [259].
Spectra taken from various LDs in the same cancer specimen are nearly identical (Figure
2.2R), which allowed quantitation of CE percentage. Given that neutral lipids in LDs are
predominantly TG and CE [81], we recorded Raman spectra of mixed emulsions
containing cholesteryl oleate and glyceryl trioleate (Figure 2.2S). We found that the
height ratio between the most prominent cholesterol band at 702 cm-1 and the CH2
bending band at 1442 cm-1 was linearly proportional to the molar percentage of CE
present in the total lipids (Figure 2.2T). Based on this calibration curve, we found that
LDs were ubiquitously rich in CE independent of the types of PCa, specifically 90.2 ±
9.1 % for low-grade, 90.6 ± 4.9 % for high-grade, and 70.3 ± 18.5 % for metastasis
(Figure 2.1O, Table 2.1). Electrospray ionization mass spectrometry analysis of extracted
lipids from tissues confirmed that CE accumulated in high-grade PCa, but not in normal
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Table 2.1 Detection of LDs and autofluorescent granules in prostate specimens from
healthy donors and PCa patients
Autofluorescent
granule

LD area
fraction (%)

Normal b
(n = 19)

Positive

ND c

BPH
(n = 10)

Positive

ND

Prostatitis
(n = 3)
PIN
(n = 3)

Low-grade PCa
(Gleason 3,
n = 9) d

High-grade
PCa
(Gleason 4/5,
n = 11) e

Metastases f
(n = 9)

a

Negative
Positive

Negative

Negative

Negative

LD area
fraction
Mean ±
SDa(%)

CE percentage
(%)

CE percentage
Mean ± SD (%)

ND

ND
0.155
1.376
0.527
0.146
0.709
0.998
2.084
0.145
0.909
3.974
2.466
6.094
4.831
4.940
1.830
3.275
3.030
6.391
1.100
5.279
1.431
3.998
3.006
4.311
3.364
3.622
0.996
2.364
1.710

0.78 ± 0.65

3.93 ± 1.74

2.76 ± 1.19

69.9
97.7
94.2
88.1
101.3
92.6
84.0
92.6
91.6
84.0
99.6
86.1
88.5
83.5
93.2
94.5
91.3
89.1
91.7
94.6
89.0
82.0
44.6
42.4
60.7
82.8
60.6
82.9
88.1

90.2 ± 9.1

90.6 ± 4.9

70.3 ± 18.5

SD = standard deviation
Normal prostate tissues were collected from healthy donors (n = 3) and PCa patients (n = 16).
c
ND = not detectable
d
Borderline cases (Gleason 3): one tissue specimen does not have any lipid accumulation; two tissue
specimens only contain autofluorescent granules but not LDs.
e
Borderline case (Gleason 4/5): one tissue specimen only contain autofluorescent granules but not LDs.
f
Metastases: liver (n = 2), lymph node (n = 3), rib (n = 1), lung (n = 1), adrenal (n = 1), and abdominal soft
tissue (n = 1)
b
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prostate, and further showed that cholesteryl oleate was the dominant species (Figure
2.2U).

2.3.2

CE Accumulation in PCa Is Not Correlated with Androgen Signaling

Because the AR remains transcriptionally active in castration-resistant PCa [185],
and cholesterol is the precursor of the entire androgen synthesis cascade, we first
speculated that CE accumulation is associated with androgen signaling in PCa. To test
this hypothesis, we examined non-transformed human prostate epithelium and a panel of
human PCa cells (Figure 2.3A, B, Table 2.2). As shown in Figure 2.3C, the LDs in nontransformed prostate RWPE1 cells showed a low CE level (< 20%), which remained low
upon addition of 10% FBS into the culture medium (Figure 2.4A). For AR-negative
cancer cells, we examined bone metastasis-derived PC-3 and brain metastasis-derived
Table 2.2 Origin, AR expression, androgen dependence, and PTEN status in various
human prostate cells
Cell lines
AR
Androgen
Origin
PTEN
expression
dependence
Normal prostate
+
Dependent
Normal
RWPE1
Lymph node
+
Dependent
Mutated
LNCaP-LP
metastasis
Lymph node
+
Independent
Mutated
LNCaP-HP
metastasis
Bone metastasis
Independent
Deleted
PC-3
Brain metastasis
Independent
Normal
DU145
Derivative of
LNCaP-LP by
+
Independent
Mutated
C4-2
passing through
castrated mice
Derivative of
CWR22 (primary
+
Independent
Normal
22Rv-1
PCa cell) by
passing through
castrated mice
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Figure 2.3 CE accumulation is not correlated with androgen signaling. (A)
SRL images of various types of cells, including RWPE1, LNCaP-LP, LNCaPHP, PC-3, DU145, and C4-2. LDs indicated by green arrows. (B) Raman
spectra of LDs in different cell lines shown in (A). Spectral intensity was
normalized by the peak at 1442 cm-1. Black arrows indicate the bands of
cholesterol rings at 702 cm-1. (C) Quantitation of LD amount and CE
percentage. LD amount was normalized by the RWPE1 group. Error bars
represent SEM. n > 5. **: p < 0.005, ***: p < 0.0005. (D) Nuclear
translocation of AR in LNCaP-LP and LNCaP-HP cells. Blue: DAPI, Red:
AR immunofluorescence. Scalar bar, 10 µm.
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Figure 2.4 CE measurements of RWPE1 and 22Rv-1 cells in various culture
conditions. (A) CE measurement of RWPE1 cells cultured in regular serumfree medium and the medium supplemented with 10% FBS. (B) SRL images
of 22Rv-1 cells treated with different concentrations of dihydrotestosterone
(DHT). DHT was diluted in phenol-red free RPMI + 10% charcoal-stripped
serum, 4 days incubation. Scalar bar, 10 µm.

DU145, and found that CE level was high in PC-3 (> 90%) but low in DU145 (< 20%).
For AR-positive cancer cells, we used low passage LNCaP (LNCaP-LP) and high
passage LNCaP (LNCaP-HP) as models for PCa progression [244]. The CE level was
high (> 80%) in the androgen-independent LNCaP-HP, but low (< 20%) in the androgendependent LNCaP-LP. Notably, LD accumulation in LNCaP-LP was reported and
attributed to the upregulation of FASN [87, 88]. Our data showed a dramatic increase of
CE levels in LDs during progression of LNCaP cells from androgen-dependent to
androgen-independent stage. Meanwhile, a key step of androgen signaling, nuclear
translocation of AR, was seen in CE-poor LNCaP-LP cells but not in CE-rich LNCaP-HP
cells (Figure 2.3D). Finally, we found, in AR-positive and androgen-independent C4-2
and 22Rv-1 cells, that CE level was low (< 20%) in C4-2 cells (Figure 2.3C) and LD
accumulation remained low upon dihydrotestosterone treatment in 22Rv-1 cells (Figure
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2.4B). These data collectively imply that CE accumulation may be linked to a pathway
that is independent of androgen signaling.

2.3.3

CE Accumulation Is Driven by Loss of PTEN and Consequent Upregulation of
PI3K/AKT/mTOR/SREBP Pathway
The finding that CE accumulated in PC-3 cells (PTEN-deleted) but not in DU145

cells (PTEN-normal) then triggered us to ask whether CE accumulation resulted from
loss of tumor suppressor PTEN, which is known to activate a pathway bypassing the AR
[185]. Loss of PTEN has been widely observed in both localized and metastatic PCa and
is correlated with high Gleason grade [260]. With loss of PTEN, PI3K signaling is
hyperactivated, which, in turn, leads to AKT activation. The upregulated PI3K/AKT
pathway has been implicated in carcinogenesis and metastasis of PCa [261, 262]. To
determine the extent to which PTEN is involved, we first reintroduced wild-type PTEN
into PC-3 cells and found CE levels to be significantly reduced (Figure 2.5A). Then, we
knockdowned PTEN in DU145 cells using shRNA and found a significant increase in CE
levels (Figure 2.5B). We further inhibited PTEN in DU145 cells using BPV (a PTEN
inhibitor) and also found a significant increase in CE levels (Figure 2.6A). To determine
the potential role of the PI3K/AKT/mTOR pathway in regulating CE accumulation, we
treated PC-3 cells (the CE-rich cell line) with LY294002 (a selective PI3K inhibitor),
MK2206 (a selective AKT inhibitor), and rapamycin (a selective mTOR inhibitor),
respectively. Although total LD amounts were not markedly reduced upon inhibitor
treatments (Figure 2.5C, D), CE levels were significantly reduced (Figure 2.5D),

46

Figure 2.5 CE accumulation is induced by loss of PTEN and activation of
PI3K/AKT pathway. (A) CE levels in PC-3 cells transfected with PTENWT
plasmid for 3 days. Raman spectra of LDs in control and PTEN-overexpressed
cells are shown on the left. The band of cholesterol rings at 702 cm-1 nearly
disappeared after the treatment, as indicated by the arrows. Quantitation of CE
percentage and LD amount is shown on the right. n > 5. (B) CE measurement
of DU145 cells transfected with PTEN shRNA lentiviral particle for 3 days.
Raman spectra of LDs in control and transfected cells are shown on the left.
The band of cholesterol rings at 702 cm-1 significantly increased after the
treatment, as indicated by the arrows. Quantitation of CE percentage and LD
amount is shown on the right. n > 5. (C) SRL images of cells treated with
DMSO as control, LY294002 (50 µM, 3d), MK2206 (10 µM, 2d), rapamycin
(100 nM, 2d), and SREBP-1 and -2 siRNA (2d transfection). LDs indicated by
green arrows. Scalar bar, 10 µm. (D) Quantitation of CE percentage and LD
amount in cells shown in (C). n > 5. (E) Immunoblot of the antibodies against
p-AKT, p-S6, SREBP-1 and -2, and β-Actin in cells treated with DMSO as
control (Ctl), LY294002 (LY), MY2206 (MK), and rapamycin (Rapa). P:
precursor form, C: cleaved form. The expression levels of p-AKT and p-S6
were reduced after inhibitor treatments as expected. Error bars represent SEM.
***: p < 0.0005.
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Figure 2.6 CE accumulation is not correlated with androgen signaling, but
rather induced by loss of PTEN and activation of PI3K/AKT pathway. (A) CE
measurement of DU145 cell treated with a potent inhibitor of PTEN, BPV(pic)
(10 µM) for 3 days. Raman spectra of LDs in control and transfected cells are
shown on the upper row. The band of cholesterol rings at 702 cm-1
significantly increased after the treatment, as indicated by the arrows.
Quantitation of CE percentage and LD amount is shown on the bottom row. n
> 5. (B) Raman spectra of LDs in PC-3 cells undergone various treatments
including LY294002 (50 µM, 3d), MK2206 (10 µM, 2d), rapamycin (100 nM,
2d), SREBP-1 and -2 siRNA (2d transfection). The bands of cholesterol rings
at 702 cm-1 were significantly reduced after the treatments, as indicated by the
arrows. (C) LD amount and CE percentage of LNCaP-HP cells treated with
DMSO as control, LY294002 (50 µM, 3d), MK2206 (10 µM, 2d), and
rapamycin (100 nM, 2d). (D) Immunofluorescence images of DAPI (blue) and
AR (red) in LNCaP-LP cells and LNCaP-HP cells treated with DMSO as
control, LY294002, MK2206, and rapamycin. (E) Immunoblot of the
antibodies against PTEN, SREBP-1 or -2 (precursor forms), and β-Actin in
control, PTEN overexpressed, SREBP-1 or -2 siRNA-transfected PC-3 cells.
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as shown by spectral analysis (Figure 2.6C). We have also inhibited
PI3K/AKT/mTOR pathway in LNCaP-HP cells and found that both LD amount and
CE levels were significantly reduced upon inhibitor treatments (Figure 2.6D). In the
meanwhile, AR translocation was still not detected in the LNCaP-HP cells upon
inhibition of PI3K/AKT/mTOR pathway (Figure 2.6E), which further supports that
CE accumulation is not correlated with androgen signaling.
It is known that AKT mediates the activation of mTOR complex 1 that plays a
critical role in regulating the function of SREBPs [69]. The SREBPs are transcription
factors that function to control lipid and cholesterol homeostasis by sensing cellular
cholesterol [70]. Increased activation of SREBPs was found in advanced PCa [183].
Using RNA interference, we found that knockdown of both SREBP-1 and -2 led to
significant reduced CE levels in PC-3 cells without affecting LD amount, and knockdown
of SREBP-1 resulted in a stronger effect than knockdown of SREBP-2 (Figures 2.5C, D,
and 2.6C). Using immunoblotting, we further found that inhibition of the
PI3K/AKT/mTOR pathway significantly suppressed both the level and cleavage of
SREBP-1 in PC-3 cells (Figure 2.5E), indicating that CE accumulation is closely related
to the activity of SREBP-1 isoforms. These results collectively suggest that CE
accumulation is regulated by the PI3K/AKT/mTOR/SREBP pathway.

2.3.4

CE Accumulation in PCa cells Arises from Enhanced Uptake of Exogenous LDL
Because cholesterol can be either de novo synthesized via the mevalonate

pathway or taken up from exogenous lipoproteins, we investigated the source of
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Figure 2.7 CE accumulation arises from enhanced uptake of exogenous LDL
and involves cholesterol esterification by ACAT-1. (A) LD amount and CE
percentage in PC-3 cells treated with or without simvastatin (10 µM, 1d), n >
5. (B) SRL images and quantitation of LD amount in PC-3 cells treated with
LPDS (10%, 1d) and subsequent LDL re-addition (45 µg/ml, 1d), n = 6. LDs
indicated by green arrows. (C) Quantitation and representative images of DiILDL uptake by PC-3 cells treated with DMSO as control, LY294002, and
rapamycin (grey: SRL, green: two-photon fluorescence), n = 5. DiI-LDL
intensity was normalized by the control group. (D) Raman spectra of LDs and
quantitation of LD amount and CE percentage in PC-3 cells treated with
avasimibe (7.5 µM, 1d) and ACAT-1 shRNA (3d transfection). n > 5. Spectral
intensity was normalized by the peak at 1442 cm-1. The bands of cholesterol
rings at 702 cm-1 nearly disappeared after the treatments, as indicated by the
arrows. LD amount was normalized by the control group in (B, D). (E) Mass
spectra of lipids extracted from control and avasimibe-treated PC-3 cells (7.5
μM, 2d). The m/z 668 peak stands for cholesteryl oleate (CE 18:1). Error bars
represent SEM. **: p < 0.005, ***: p < 0.0005. Scalar bar, 10 µm. LPDS:
lipoprotein deficient serum; DiI-LDL: DiI-LDL.
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cholesterol used for CE accumulation. We first treated PC-3 cells with simvastatin, an
inhibitor of HMGCR, the rate-limiting enzyme of the mevalonate pathway. As shown in
Figure 2.7A, simvastatin neither decreased LD amount nor significantly reduced CE
levels. In contrast, after treating cells with lipoprotein-deficient serum, LDs nearly
disappeared in CE-rich PC-3 cells (Figure 2.7B), but remained the same amount in CEpoor cells, including LNCaP-LP, DU145, and C4-2 (Figure 2.8A-B). Re-addition of LDL
into the lipoprotein-deficient medium restored LDs in PC-3 cells (Figure 2.7B) and the
CE level in these LDs was 93.6 ± 5.5 %. By treating cells with DiI-LDL, it was found
that LDL uptake was the most prominent in the CE-rich PC-3 cells compared to CE-poor
PCa cells (Figure 2.8C-D). Moreover, inhibition of the PI3K/AKT/mTOR pathway
significantly reduced expression levels of LDLr (Figure 2.8E) and blocked the uptake of
DiI-LDL in PC-3 cells (Figure 2.7C). Knockdown of SREPB-1 using siRNA also
reduced the LDL uptake in PC-3 cells (Figure 2.8F). These results collectively indicate
that exogenous LDL is the primary source for CE accumulation.

2.3.5

CE Accumulation in PCa Cells Requires Cholesterol Esterification by ACAT-1
LDL is known to enter a cell via LDLr and traffic to the late endosome and

lysosome to be hydrolyzed to FFAs and free cholesterol. The excess free cholesterol
together with the fatty acyl CoA substrate is then converted to CE by ACAT and stored in
LDs [170]. Thus, we treated cells separately with avasimibe and Sandoz 58-035, two
different ACAT inhibitors. Both inhibitors effectively suppressed CE accumulation in
PC-3 cells (Figures 2.7D, 2.8G), with the amount of LDs slightly decreased (Figure 2.7D).
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Figure 2.8 LDs in CE-poor cells do not arise from exogenous LDL, whereas
CE accumulation in CE-rich cells arises from enhanced uptake of exogenous
LDL. (A-B) Representative SRL images and quantitation of LD amount of
various CE-poor cancer cells, including LNCaP-LP, DU145, and C4-2, before
and after LPDS treatment (1d). LD amounts in cells before treatments were
normalized for each cell line. (C-D) Representative images and quantitation of
DiI-LDL uptake in various cell lines, including RWPE1, LNCaP-LP, LNCaPHP, PC-3, DU145, and C4-2. DiI-LDL treatment: 20 µg/ml for 3 hr. Grey:
SRL; Green: two-photon fluorescence. (E) Immunoblot of the antibodies
against LDLr, ACAT-1, and β-Actin in PC-3 cells treated with DMSO as
control, LY294002 (50 µM, 3d), MK2206 (10 µM, 2d), and rapamycin (100
nM, 2d). (F) Quantitation of DiI-LDL uptake in PC-3 cells transfected with
SREBP-1 siRNA. (G) SRL images and Raman spectra of LDs in PC-3 cells
with and without Sandoz 58-035 treatment (10 µM, 1d). The bands of
cholesterol rings at 702 cm-1 nearly disappeared after the treatments, as
indicated by the arrows. (H) Effect of avasimibe treatment (7.5 μM, 2d) on
fraction of CE out of total cholesterol in PC-3 cells, measured by biochemical
assay. (I) Relative levels of cholesteryl oleate (CE 18:1) in control and
avasimibe-treated PC-3 cells (7.5 μM, 2d), measured by mass spectrometry
and normalized by cell number (n = 3). (J) Immunoblot of the antibodies
against ACAT-1 and β-Actin in control and ACAT-1 siRNA-transfected PC-3
cells. Scalar bar = 10 µm. Error bars represent SEM. *: p < 0.05. **: p < 0.005,
***: p < 0.0005. LPDS: lipoprotein deficient serum; DiI-LDL: DiI-LDL.
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The significant reduction of CE accumulation upon avasimibe treatment was verified by
biochemical assay (Figure 2.8H) and mass spectrometry of extracted lipids from PC-3
cells (Figures 2.7E, 2.8I). The mass data further showed that cholesteryl oleate was the
dominant species present. Because avasimibe inhibits both ACAT-1 and -2 isoforms, we
specifically knocked down ACAT-1 using shRNA and found significant reduction of the
CE level in PC-3 cells (Figures 2.7D, 2.8J). In addition, inhibition of PI3K/AKT/mTOR
pathway significantly reduced expression levels of ACAT-1 (Figure 2.8E). These results
collectively confirm the involvement of ACAT-1 in CE storage in PCa cells.

2.3.6

Pharmacological Depletion of CE Storage Impairs PCa Aggressiveness

Because CE accumulation was found in PCa but was not detectable in normal
prostate, we evaluated how cell viability could be affected by regulating CE levels with
ACAT inhibitors. As shown in Figure 2.9A and Figure 2.10A, treatments of two ACAT
inhibitors, avasimibe and Sandoz 58-035, significantly reduced viability of PC-3 cells,
with IC50 value of 7.3 µM and 17.2 µM, respectively. The inhibitory effect of avasimibe
on the growth of PC-3 and LNCaP-HP cells was considerably greater than that in CEpoor PCa cells, including LNCaP-LP, DU145, and C4-2 (Figure 2.10B), with IC50 value
of 9.6 µM in LNCaP-HP cells (Figure 2.10C). Results from flow cytometry analysis
(Figure 2.9B) revealed that exposure of PC-3 cells to avasimibe resulted in both cell
cycle arrest and apoptosis, i.e. the G2/M phase population was ~2 times smaller whereas
the sub-G1 population was ~3 times larger in avasimibe-treated group compared to
control group. To confirm the effect of ACAT inhibition on cell viability, we treated PC3 cells with a potent and selective inhibitor of diacylglycerol acyltransferase (DGAT)-1,
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Figure 2.9 CE depletion impairs human PCa aggressiveness. (A) IC50 curves
of avasimibe and Sandoz 58-035 treatments on PC-3 cells. n = 6 per group. (B)
Flow cytometry analysis of cell cycle in control and avasimibe-treated PC-3
cells (n = 3). (C, D) Quantitation of migrated and invaded PC-3 cells that were
pretreated with DMSO as control, avasimibe (5 µM), Sandoz 58-035 (SaH, 10
µM), and ACAT-1 shRNA for 2d (n = 3). And quantitation of migrated and
invaded PTEN knockdown (PTEN-KD) DU145 cells that were pretreated
with DMSO as control and avasimibe (5 µM) for 1d (n = 3). (E) Relative
tumor volume of PC-3 xenograft (n = 9). Relative tumor volume = tumor
volume / initial tumor volume (day 0) for each mouse. Representative tumors
harvested on day 30 are shown in the inset. Scalar bar, 1 cm. (F) Weight of
tumor tissues harvested from mice (n = 8). (G) Body weight of mice over 30day treatments (n = 9). (H) CE percentage of tumor tissues harvested from
mice (n = 5). (I) Representative images of H&E staining, IHC of Ki67, and
TUNEL labeling (blue: DAPI, cyan: TUNEL-positive) of vehicle and
avasimibe groups. Scalar bar, 100 µm. (J) Percentage of Ki67 and TUNEL
positive cells in vehicle and avasimibe groups (n = 5). Error bars represent
SEM. *: p < 0.05, **: p < 0.005, ***: p < 0.0005.
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which catalyzes the terminal step of TG formation, and found that DGAT inhibition did
not affect cell viability until high doses (Figure 2.10C). We also showed that specific
knockdown of ACAT-1 using shRNA significantly reduced viability of PC-3 cells
(Figure 2.10D). Moreover, ACAT inhibition by avasimibe significantly suppressed
viability of PTEN knockdown DU145 cells (Figure 2.10D). To evaluate whether CE
depletion affects tumor aggressiveness, we conducted standard transwell assays and
found that both migration and invasion capabilities of PC-3 cell were markedly
suppressed upon ACAT inhibition by avasimibe, Sandoz 58-035, and ACAT-1 shRNA
(Figures 2.9C, D, 2.10E). And also in PTEN knockdown DU145 cells, ACAT inhibition
by avasimibe significantly suppressed cell migration and invasion capabilities (Figure
2.9C, D). In contrast, DGAT inhibition slightly increased PC-3 cell migration and
invasion (Figure 2.10F). Notably, negligible toxic effects on non-transformed prostate
RWPE1 cells were found at the same dose of avasimibe treatments (Figure 2.10B).
To test the potential of using ACAT inhibition to treat advanced PCa in vivo, we
administered two ACAT inhibitors, avasimibe and Sandoz 58-035 (15 mg/kg, via
intraperitoneal injection), to athymic nude mice bearing PC-3 xenografts. Daily treatment
of mice with ACAT inhibitors inhibited the growth of PC-3 tumors by ~2 fold (Figures
2.9E, 2.10G), and significantly reduced weight of tumor tissues (Figures 2.9F, 2.10H).
Importantly, ACAT inhibitors did not cause general toxicity to animals, as indicated by
no change observed in animal behavior or body weight (Figures 2.9G, 2.10I).
Pathological review of sections of heart, kidney, liver, lung, and spleen harvested from
mice receiving avasimibe showed no detectable signs of toxicity (Figure 2.10J).
Spectroscopic imaging of extracted tissues revealed that CE levels significantly dropped
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Figure 2.10 CE depletion using various ACAT inhibitors or RNA interference
suppresses PCa viability and growth in vivo with negligible toxicity. (A)
Proliferation curves of control and avasimibe-treated PC-3 cells (n = 6). (B)
Viability of various cell lines, including RWPE1, LNCaP-LP, LNCaP-HP,
PC-3, DU145, and C4-2, treated with avasimibe. n = 6 per group. (C) IC50
curves of avasimibe treatment on LNCaP-HP cells and DGAT-1 inhibitor
A922500 treatment on PC-3 cells. n = 6 per group. (D) Viability of PC-3 cells
transfected with ACAT-1 shRNA for 3 days. And viability of PTEN
knockdown (PTEN-KD) DU145 cells treated with avasimibe (7.5 µM) for 2
days. (E) Images of migration and invasion of PC-3 cells pre-treated with
avasimibe (5 µM, 2d). Red: PI staining. Scalar bar, 50 µm. (F) Quantitation of
migrated and invaded PC-3 cells pre-treated with DGAT-1 inhibitor A922500
(10 µM, 2d), n = 3. (G) Relative tumor volume of PC-3 xenograft (n = 8). (H)
Weight of tumor tissues (n = 8). (I) Body weight of mice (n = 8). (J) H&E
staining of tissue sections. Scalar bar, 100 µm. (K) Raman spectra of PC-3
tumor tissues. Error bars represent SEM. *: p < 0.05. **: p < 0.005, ***: p <
0.0005.
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Figure 2.11 CE depletion reduces human PCa cell proliferation by limiting
uptake of essential fatty acids. (A) Free cholesterol level in control (Ctl:
DMSO as control) and avasimibe (Ava)-treated PC-3 cells (n = 3). (B)
Immunoblot of the antibodies against SREBP-1 and -2, LDLr, p-AKT, and βActin in ACAT-1 knockdown PC-3 cells. P: precursor form, C: cleaved form.
(C) Quantitation and representative images and of DiI-LDL uptake in control
and avasimibe-treated PC-3 cells (n = 5). Grey: SRL; Green: two-photon
fluorescence. Scalar bar, 10 µm. DiI-LDL intensity was normalized by the
control group. (D) AA levels in control and avasimibe-treated PC-3 cells (n =
3). (E) PC-3 cell viability upon AA treatments. (F) PC-3 cell viability upon
AA and/or avasimibe treatments. Viability was measured by MTT assay. The
absorbance value measured for control group was used for normalization.
Comparisons were made between control and treated groups (n = 6 per group).
Error bars represent SEM. *: p < 0.05, ***: p < 0.0005.

in avasimibe-treated tumors compared to vehicle-treated ones, even though LD area
fraction was not affected (Figures 2.9H and 2.10K), indicating that ACAT inhibitor
worked to inhibit CE formation in tumor cells in vivo. IHC using markers for
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proliferation (Ki67) and apoptosis (TUNEL) showed that ACAT inhibitor avasimibe
significantly reduced tumor proliferation by ~70% and increased apoptosis by ~2 fold
(Figure 2.9I, J).

2.3.7

CE Depletion Impairs PCa Growth by Limiting Uptake of Essential Fatty Acids
We first suspected that CE storage might act as a pool of fatty acid and

cholesterol which can be released from LDs for cancer cell proliferation. The result that
inhibition of CE hydrolysis using diethylumbelliferyl phosphate, a selective cholesterol
esterase inhibitor, slightly enhanced PC-3 cell growth (Figure 2.12A) excluded such
possibility. We then asked whether CE depletion suppresses PCa proliferation by
downregulation of the upstream pathways including LDL uptake. We notice that LDL is
the primary carrier of essential PUFAs, including AA [263]. Inside cells, AA is released
from LDL and converted to a range of eicosanoids that have been implicated in various
pathological processes, including inflammation and cancer [77]. Because cholesterol
esterification is known to play a vital role in maintaining intracellular cholesterol
homeostasis [170], we hypothesized that abrogating ACAT activity can inhibit PCa
growth by elevating free cholesterol levels, downregulating expression levels of SREBP
and LDLr, and consequently reducing the uptake of LDL. To test this hypothesis, we
measured free cholesterol levels in PC-3 cells with a biochemical assay and found that
avasimibe treatment significantly increased the free cholesterol levels (Figure 2.11A).
Immunoblotting measurement showed that ACAT inhibition by specific knockdown of
ACAT-1 using shRNA and the two ACAT inhibitors (avasimibe and Sandoz 58-035)
resulted in reduced cleavage of SREBP-1 and downregulation of expression levels of
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Figure 2.12 Mechanistic studies about the effects of ACAT-1 inhibition on
intracellular cholesterol homeostasis. (A) Viability of PC-3 cells treated with
different concentrations of CE hydrolase inhibitor, diethylumbelliferyl
phosphate (DEUP), for 3 days. (B) Immunoblot of the antibodies against
SREBP-1, -2, LDLr, p-AKT, and β-Actin in PC-3 cells treated with avasimibe
(7.5 µM, 3d) and Sandoz 58-035 (SaH, 10 µM, 3d). P: precursor form, C:
cleaved form. (C) AA levels in control and avasimibe-treated LNCaP-HP cells
(n = 3). (D) PC-3 cell viability upon LDL treatments. Viability was measured
by MTT assay. The absorbance value measured for control group was used for
normalization. Comparisons were made between control and treated groups (n
> 6 per group). Error bars represent SEM. *: p < 0.05, **: p < 0.005, ***: p <
0.0005.

SREBP-1, and LDLr (Figures 2.11B, 2.12B). We further monitored cellular uptake of
DiI-LDL upon ACAT inhibitor treatment, and found that avasimibe treatment resulted in
reduced LDL uptake by ~10 fold (Figure 2.11C). Further, liquid chromatography-mass
spectrometry analysis of cell lysates revealed that ACAT-1 inhibition by both inhibitor
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avasimibe and shRNA significantly reduced the level of AA in PC-3 cells (Figure 2.11D),
and avasimibe also significantly reduced AA levels in LNCaP-HP cells (Figure 2.12C).
As shown elsewhere [264, 265] and confirmed herein, LDL and AA separately promoted
the growth of PC-3 cells in a dose-dependent manner (Figure 2.11E, 2.12D). AA was also
shown to rescue the inhibitory effect of ACAT inhibitor avasimibe on cancer cell
viability (Figure 2.11F). Moreover, expression levels of p-AKT were significantly
reduced upon ACAT-1 inhibition in PC-3 cells (Figures 2.11B, 2.12B). This might be
caused by reduced levels of AA, which has been shown to activate PI3K/AKT signaling
in PCa [266]. These data collectively provide evidence that ACAT inhibition might have
hindered proliferation of CE-rich PCa cells by limiting the uptake of a critical
proliferative factor, AA, via downregulation of LDLr. The molecular basis for CE
accumulation and the impact of CE depletion on PCa proliferation are summarized in
Figure 2.13.

2.4

Discussion

Through integrated analyses of PCa clinical samples, cell lines, and mouse
xenograft model, we have revealed a novel role of CE, a lipid metabolite, in human PCa
progression. CE accumulation is known to be a hallmark of atherosclerosis and hormoneproducing organ [81, 267], however its exact role in cancer progression remains elusive.
In this study, prominent CE accumulation that only occurs in advanced PCa is shown to
be a consequence of the loss of tumor suppressor PTEN and subsequent activation of
PI3K/AKT/mTOR pathway. Blockage of CE accumulation significantly impairs PCa
aggressiveness without inducing toxicity. As discussed below, these findings improve
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Figure 2.13 Molecular pathways underlying accumulation of CE in advanced
human PCa and suppression of cancer proliferation upon CE depletion. The
schematic shows that loss of tumor suppressor PTEN activates
PI3K/AKT/mTOR pathway, which in turn upregulates SREBP and LDLr.
LDL is then hydrolyzed to FFAs and free cholesterol (FC) in lysosome. The
excess FC together with the fatty acyl CoA substrate is converted to CE by
ACAT-1 and stored in LDs. LDL also serves as an important carrier of ω-6
PUFA, such as AA, which promotes cell proliferation and tumor growth. The
red arrows depict the consequences of CE depletion. Depletion of CE storage
by specific ACAT-1 knockdown using RNA interference or ACAT inhibitors
disturbs cancer cell cholesterol homeostasis by elevating FC levels and
consequently downregulating expression levels of SREBP and LDLr.
Subsequently reduced uptake of ω-6 PUFA from LDL suppresses cancer
proliferation.

current understanding of the role of cholesterol in cancer and also open new opportunities
for diagnosis and treatment of aggressive PCa.
First, our study contributes to the understanding of metabolic pathways that drive
PCa progression. Increasing evidence supports that androgen signaling pathways remain
active throughout every stage of PCa progression [185]. However, expression levels of
AR are heterogeneous and even absent in some metastases [268]. Such clinical
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observations suggest that PCa cells may also depend on other compensatory signaling
pathways to survival and grow. One of the most important pathways that bypass AR is
the PI3K/AKT/mTOR pathway, which is negatively regulated by the tumor suppressor
PTEN. PTEN has been identified as one of the most commonly lost or mutated tumor
suppressor genes in human cancers [269]. In particular, nearly 70% of advanced PCa
exhibit loss of PTEN or consequent activation of the PI3K/AKT pathway [270], which
leads to enhanced cell survival, proliferation, migration, invasion, metastasis, and
castration-resistant growth as well [261, 270, 271]. Our results, as illustrated in Figure
2.13, show that PTEN loss induces CE accumulation by activating the PI3K/AKT/mTOR
pathway and subsequently upregulating the expression levels of SREBP and LDLr. This
finding elucidates the mechanism by which tumor suppressor PTEN regulates metabolic
pathways to meet the increased demand of aggressive PCa cell for LDL cholesterol
uptake. Our study further showed that such enhanced LDL uptake is linked to AA, a
proliferation factor of PCa [264, 265].
Whereas alterations to metabolism of glucose, amino acids, and fatty acids have
been extensively studied [8], cholesterol metabolism in cancer is a relatively understudied
field [21]. Inside cells, cholesterol is an essential molecule that plays important roles in
the maintenance of membrane structure, signal transduction, and provision of precursor
to hormone synthesis [93]. As early as 1942, increased level of free cholesterol in the
adenoma of enlarged prostates was reported by analysis of tissue homogenates [272].
More recently, immunohistochemical staining of PCa bone metastases showed intense
staining of the LDLr, which supports the important role of LDL uptake in PCa
progression [176]. However, the molecular mechanisms by which advanced PCa cells
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obtain sufficient cholesterol and in the meanwhile maintain intracellular cholesterol
homeostasis remain poorly understood. Our imaging study of human tissues identified a
possible culprit, that is, accumulation of esterified cholesterol in LDs of advanced PCa
cells. Advanced PCa cells take advantage of the esterified form not only to avoid toxicity
of excess cholesterol [170], but also to keep free cholesterol at relatively low level so that
SREBP, which controls cholesterol biogenesis, is always active. This mechanism
explains why PCa cells could maintain high expression levels of SREBP and LDLr even
in the presence of exogenous cholesterol [175].
We note that statin use has been linked with a decreased risk of advanced PCa
[273], and its benefits against PCa were found to be based on systemic cholesterollowering effect rather than direct effect on de novo cholesterol synthesis [274]. In
accordance, our cellular studies reveal that cholesterol stored in the LDs of advanced PCa
cells is not synthesized de novo, but rather derived from enhanced uptake of exogenous
LDL. Using mass spectrometry, we find that cholesteryl oleate is the dominant species of
CE inside the LDs. This result suggests that LDL with cholesteryl linoleate as the
dominant form is hydrolyzed into free cholesterol and then re-esterified to CE by ACAT1. Together, our finding offers a biological foundation that supports the beneficial effect
of cholesterol-lowering drugs.
Second, our study opens a possibility of distinguishing the aggressive forms of
PCa from the indolent ones that can be left without treatment. Since the introduction of
prostate specific antigen screening, PCa has become the most widely diagnosed non-skin
cancer in men in the United States [275]. The fact that 1410 men need to be screened and
48 cases of PCa need to be treated to prevent one death [276] has raised a controversy not
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only about the usefulness of prostate specific antigen screening, but also about the
clinical management, of PCa. Indeed, most PCa are slowly growing, and only the
aggressive ones eventually spread to other organs and require early diagnosis and
effective treatment. The current standard for PCa diagnosis remains biopsy and
histopathology. While PCa with Gleason score ≤ 6 (e.g. 3+3) is considered to be low-risk
and is left without active treatment, PCa with Gleason score ≥ 7 (e.g. 3+4) is considered
to be high-risk and is often treated with radical prostatectomy, androgen deprivation
therapy, radiation, and/or chemotherapy. Nonetheless, the subjective nature of
histopathology leads to inevitable discordance among pathologists. Especially for the
differentiation between Gleason score 6 and 7, the inter-observer discordance can be up
to 40% [277], which may result in overtreatment for some low-risk tumors and
undertreatment for some high-risk tumors. Our study provides an opportunity towards
more accurate prediction of aggressiveness. Because CE accumulation is quantifiable and
is significantly (~5 fold) greater in Gleason grade 4/5 compared to that in Gleason grade
3, it presents a promising molecular marker to improve the current PCa diagnosis.
Notably, massive CE accumulation only occurs in metastases and most of, but not all,
high-grade PCa (Table 2.1). Moreover, depleting CE significantly impairs PCa
aggressiveness, including survival, migration, invasion, and growth in vivo. These results
together suggest that CE accumulation might be used for more accurate prediction of PCa
aggressiveness. We note that validation of CE as an aggressiveness marker necessitates
further examination of a large number of tissue biopsies and correlation assessment of CE
levels and clinical outcomes of patients.
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Third, our study heralds the potential of using CE as a therapeutic target for
treatment of advanced PCa. While often diagnosed in clinically localized stages, PCa
remains the second leading cause of cancer-related mortality in American men with over
28,000 projected deaths in 2012 [275].

For men with advanced PCa, androgen

deprivation therapy is an accepted standard therapy. Despite initial disease control,
androgen deprivation therapy alone is non-curative and the subsequent development of
castration-resistant PCa occurs in the lifespan of almost all men who do not succumb to
non-cancer deaths [185]. There has been a tremendous increase in treatment options
available for metastatic castration-resistant PCa patients, including novel anti-androgen
therapy [278] and others. Nevertheless, the effectiveness of current therapies is palliative
with an improvement in overall survival of 2-5 months compared to placebo. In this study,
we show that CE depletion by abrogating ACAT activity with avasimibe significantly
hinders advanced PCa growth via cell cycle arrest and apoptosis induction. One possible
explanation for such anti-cancer effect of avasimibe, as illustrated in Figure 2.13, is that
depleting CE storage disrupts intracellular cholesterol homeostasis and consequently
reduces the uptake of essential fatty acids, such as AA, which stimulates PCa growth and
progression [264, 265]. Because CE depletion leads to elevation of free cholesterol levels,
apoptosis induced by avasimibe could be due to free cholesterol toxicity. The alteration
of cholesterol metabolism might also be linked to regulation of lipid rafts in PCa [193].
Importantly, the CE-depleting drug does not cause detectable toxicity in the nontransformed cell or in the mouse model. Owing to the much stronger dependence of
advanced PCa on CE compared to its normal counterparts, cholesterol esterification may
be a cancer-specific target for developing an effective, non-toxic anti-cancer therapy.
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Blockage of cholesterol esterification with ACAT inhibitors was used to treat
lymphocytic leukaemia [197], glioblastoma [279], and breast cancer [280] cells in vitro.
In this work, we demonstrated, for the first time, its effectiveness in suppressing growth
of aggressive tumor in vivo. We note that avasimibe was previously used to treat
atherosclerosis [256] but halted by Pfizer due to the lack of effectiveness in reducing
plaque size. Thus, the present study highlights a novel use of avasimibe to treat advanced
PCa. Collectively, abrogating ACAT-1 activity offers a potentially effective way of
treating advanced PCa.
Finally, given that the PI3K pathway is hyperactivated not only in advanced PCa,
but also in many other human cancers, including brain, breast, renal, lymphocyte,
cervical, and lung [67], CE accumulation in LDs might be a common characteristic of
PI3K-driven cancers. Indeed, CE was found to be a proliferative factor for leukemia
[197]. And dysregulation of cholesterol metabolism in glioblastoma was shown to be
driven by PI3K pathway [179]. Future elucidation of the molecular mechanisms by which
PI3K pathway differentially regulates cholesterol metabolism in cancer cells from
multiple tissues of origin will determine whether CE is a compelling drug target across
multiple cancer types. Such studies will further improve current understanding of how
metabolic reprogramming is linked to oncogenic transformation.

66

CHAPTER 3. LABEL-FREE ANALYSIS OF BREAST TISSUE POLARITY BY
RAMAN IMAGING OF LIPID PHASE

The work presented in this chapter was published in Biophysical Journal [281].
Reprinted with permission from [281]. Copyright © 2012 Biophysical Society.
The formation of the basoapical polarity axis in epithelia is critical for
maintaining the homeostasis of differentiated tissues. Factors that influence cancer
development notoriously affect tissue organization. Apical polarity appears as a specific
tissue feature that, once disrupted, would facilitate the onset of mammary tumors. Thus,
developing means to rapidly measure apical polarity alterations would greatly favor
screening for factors that endanger the breast epithelium. A Raman scattering based
platform was used for label-free determination of apical polarity in live breast glandular
structures (acini) produced in 3D cell culture. The CARS signal permitted the
visualization of the apical and basal surfaces of an acinus. Raman microspectroscopy
subsequently revealed that in polarized acini lipids were more ordered at the ApM
compared to BaM, and that an inverse situation occurred in acini that lost apical polarity
upon treatment with Ca2+-chelator EGTA. This method overcame variation between
different cultures by tracking the status of apical polarity longitudinally for the same acini.
Therefore the disruption of apical polarity by dietary breast cancer risk factor, ω6 fatty
acid, could be observed with
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this method, even when the effect was too moderate to permit a conclusive assessment by
traditional immunostaining method.
3.1

Introduction

With advantages over conventional 2D cell culture models that they provide by
mimicking tissue-specific architectures and functions, 3D cell culture models have been
increasingly used in a broad range of research, including epithelial morphogenesis, tumor
biology, cell migration, regenerative medicine, and drug screening [282-284]. In
particular, increased knowledge in mammary gland morphogenesis and neoplastic
transformation has been obtained from studies using 3D culture of different types of
mammary epithelial cells that take into account alterations in tissue architecture (i.e., the
specific cellular organization within an assembly of cells) to decipher the mechanisms
that control cell proliferation, survival, differentiation and resistance to chemotherapeutic
drugs [285-295]. However, a wide implementation of the evolving paradigm of
physiologically relevant 3D culture has been hampered by the lack of proper visualization
tools to study tissue phenotypes. A tremendous challenge to quantitatively measure
cellular responses in 3D cultures by conventional fluorescence microscopy is the
inefficient diffusion of fluorescent dyes in thick tissue samples [283] and the fluorescent
background triggered by the ECM used as cell culture substratum [296]. Continuous
analyses of cellular responses over periods of time are limited to bright field microscopy
and the occasional GFP-tagged expression of a specific protein. Therefore, innovations in
label-free analysis of cellular responses are crucial to fully exploit the benefits of 3D
cultures.
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An important area of investigation is the alteration of tissue architecture that
precedes tumor development. Inhibiting or reversing such alterations would play a key
role in the design of prevention interventions that are so much needed. A number of
factors that favor cancer development have been associated with changes in tissue
architecture. Indeed, epidemiological and/or animal studies reported that estrogen and
high fat diet [297], as well as obesity [298] and alcohol consumption [299] could modify
mammary morphogenesis (notably the density of epithelial structures, a factor known to
influence breast cancer risk).

Figure 3.1 Organization of Mammary Acinus. TJ: tight junction; D:
desmosome; GJ: gap junction.

Models that mimic phenotypically normal breast glandular differentiation exist
and have been used to unravel pathways involved in the initiation of tumors. Cells are
cultured in the presence of EHS-derived ECM, which resembles a BM, and functionally
reproduce mammary glandular structures (acini) with, for certain cell lines like the HMT-
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3522 S1, complete tissue polarity axis [290, 295, 296] (Figure 3.1). This axis largely
determines the functional integrity of epithelia and includes both apical polarity and basal
polarity [292, 300, 301]. Basal polarity is determined by the presence of specific cell-BM
contacts [292]. Apical polarity is characterized by the polarized distribution of
cytoplasmic organelles [301-304] and the segregation and retention of specific proteins
and lipids in distinct ApM and BaM domains due to the presence of apical tight junctions
[305, 306]. Functionally, the BaM facing the extracellular compartment maintains
differentiation and survival, whereas the ApM facing the luminal (external) compartment
mediates physiological states (e.g., quiescence) and exchange functions (e.g. absorption
and secretion) [301]. Tight junctions are formed by transmembrane proteins connected to
cytoplasmic proteins at the most apical side of cell-cell junctions [307, 308]. The
redistribution of tight junction proteins away from apical sites is an indicator of the
disruption of apical polarity [309-311]. Importantly, proteins normally located at the
apical junctional complex have been implicated in the control of tumor development [295,
312]. Moreover, loss of apical polarity is necessary for cell cycle entry, and is one of the
earliest changes observed in tissue architecture in breast neoplasia [293, 295, 313].
Interestingly, smoking, the key factor in the development of lung cancer, has been shown
to alter apical polarity in the lung epithelium [314]. Therefore the status of tissue polarity
constitutes a critical readout to assess epithelial integrity and homeostasis.
Currently, immunofluorescence imaging of fixed cell culture for apical polarity
markers is needed to determine the status of apical polarity. This method prevents
dynamic screening of factors that could control epithelial homeostasis. Also the
percentage of apically polarized mammary acini in 3D culture varies from 60% to 80%
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[293, 313, 315]. Consequently loss of apical polarity in a small, yet significant fraction of
the acini population might be easily blurred by variation between different cultures. Thus,
a large number of acini have to be analyzed to achieve statistical significance, which
implies ineffectiveness of the current immunostaining method.
In polarized epithelial cells, not only proteins but also lipids are differentially
distributed on apical and BaM [303, 304]. The ApM is strongly enriched in sphingolipids,
which, together with cholesterol, form continuous liquid-ordered assemblies with
restricted mobility. In contrast, the BaM has less raft coverage and thus, is in a less
ordered phase [303, 304]. Different degrees of lipid ordering have been shown to produce
distinct Raman spectral profiles in live tissues [316-318], which opens the possibility for
applying this method to 3D cultures of mammary acini.
As a non-invasive and label-free analytical method, Raman spectroscopy has been
widely used in biomedical research [319]. In particular, the analysis of lipid composition
by Raman spectroscopy is well established in the skin [318], eye lens [317], and nerve
fibers [320]. Since the first measurement of living cells [321], Raman spectroscopy has
been extensively applied to quantitative studies of biological systems [322-324].
However, the application of Raman scattering to high-speed biological imaging is
hindered by the very weak spontaneous Raman signals. In order to enhance the signal
level, CARS microscope has been developed [325]. By focusing the excitation energy on
the single Raman band and coherent addition of the scattering field, single-frequency
CARS microscopy has been employed to visualize lipid-rich structures, including cellular
membranes, myelin sheath, and adipocytes, at the speed of a few microseconds per pixel,
on a laser-scanning microscope platform [326-328]. To offer spectral information,
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multiplex CARS (M-CARS) microscopy using a narrowband and a broadband pulse has
been developed [329, 330] and applied to the study of LDs in 3T3-L1 cells at a speed of
20 ms per pixel [331, 332]. Another important development is hyperspectral CARS
enabled by automatic wavelength scanning of a picosecond laser [333].
To fully appreciate the potential of high-speed vibrational imaging by CARS and
quantitative spectral analysis by spontaneous Raman, Cheng and coworkers developed a
compound Raman microscope that couples fast CARS imaging of a live biological
sample with confocal Raman spectral analysis at points of interest [334]. The compound
Raman microscope has been applied to quantitative analysis of LDs in live cells, tissues,
and model organisms [334, 335].
In this work, we present a new application of compound Raman microscopy to
label-free analysis of live cell membrane in 3D culture. Specifically we investigate how
lipid ordering of ApM and BaM could be used to characterize apical polarity in live
mammary acini. We took advantage of a high-throughput cell culture technique that
permits the formation of acini in the presence of diluted EHS on a glass surface [313],
enabling direct microscopic evaluation of apical polarity. We note that cell morphology
and organization in 3D culture are completely different from those in flat monolayer
culture. The cells in the acini tightly adhere together to form ball-like ApM and BaM,
with diameter of 5 and 30 µm, respectively. This feature allowed acquisition of confocal
Raman spectra of ApM and BaM with lateral resolution around 0.4 µm and axial
resolution around 4 µm. By fast CARS imaging followed by confocal Raman
spectroscopy of membranes at the equatorial plane of live acini, we show that the relative
degree of lipid ordering of ApM compared with BaM effectively distinguishes polarized
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(P) and nonpolarized (Non-P) mammary epithelia with high sensitivity and specificity.
This method offers new opportunities for the study of environmental factors that
influence epithelial homeostasis.

3.2
3.2.1

Experimental Section

3D Culture of Human Mammary Acini

Non-neoplastic human mammary epithelial HMT-3522 S1 cells were cultured at
37ºC in 5% CO2, in chemically defined H14 medium. H14 medium consists of
DMEM/F12 (Gibco/BRL, St Louis, MO) with 250 ng/ml insulin (Boehringer Mannheim,
Indianapolis, IN), 10 µg/ml transferrin (Sigma, St Louis, MO), 2.6 ng/ml sodium selenite
(BD Biosciences, Bedford, MA), 10–10 M estradiol (Sigma), 1.4 µM hydrocortisone (BD
Biosciences), 5 µg/ml luteotropic hormone (Sigma), and 10 ng/ml EGF (EGF; BD
Biosciences). H14 medium was routinely changed every 2-3 days. The high-throughput
3D culture was previously described (Ref. 32). Briefly cells were plated at a density of
41,520 cells / cm2 in half the volume of medium for each 35 mm glass bottom dish. The
other half of the medium containing 10% EHS material from Matrigel™ (BD Bioscience)
was dripped on top of cells 5 min after cell seeding. The culture medium was changed
every two to three days with EGF omitted after day 7. Acinar morphogenesis is routinely
observed by day 8 to 10.
Treatment with disruptors of apical polarity was applied upon acini formation.
Incubation with 1.5 mM EGTA began from day 10 and lasted for 24 hours, a time frame
shown to effectively disrupt apical polarity in the majority of mammary acini [293].
Treatment with 60 µM AA (Cayman Chemical) was performed from day 8 to day 12 of
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3D culture. The same H14 medium was used throughout the treatments with different
modulators of apical polarity. As shown in Figure 3.2, we were able to track the same
mammary acini, in gridded glass-bottom culture dishes, undergoing treatment by
transmission and CARS imaging.

Figure 3.2 Longitudinal tracking of acini undergoing treatments to disrupt
apical polarity. Acini were grown on gridded glass bottom culture dishes for
10 days using the high throughput method. They were located by CARS and
transmission microscopy imaging before and after treatment with either
EGTA or AA. Scale bars, 50 µm.

3.2.2

Immunostaining

Immunofluorescence staining of cells in 3D culture was performed as previously
described [315]. Cells were permeabilized with 0.5% Triton X-100 (Sigma) for 15 min in
cytoskeleton buffer [100 mM NaCl, 300 mM Sucrose, 10 mM Pipes pH 6.8, 5 mM
MgCl2, 1 mM pefabloc, 10 µg/ml aprotinin, 250µM NaF], then fixed in 10% formalin
(Sigma) for 20 minutes at room temperature. Antibodies against ZO-1 (Invitrogen catalog
# 339100; 5 µg/ml final concentration), ZO-2 (Invitrogen # 37-4700, 10 µg/ml final
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concentration), and hScrib (Santa Cruz catalog # SC-55543, 5 µg/ml final concentration)
were used. Alexa Fluor 488 phalloidin (Molecular Probes, 5 units/ml final concentration)
was used to image polymerized actin. Nuclei were stained with 4’, 6-diamino-2phenylindole (DAPI; 0.5µg/ml) and samples were mounted in ProLong antifade solution
(Molecular Probes) and stored at -20ºC until use.

3.2.3

Compound Raman Microscopy and Spectrum Analysis

A compound Raman microscope, which integrates CARS and confocal Raman
microspectroscopy on the same platform, was used for label-free analysis of apical
polarity. In our apparatus, two synchronized 5-ps, 80 MHz laser oscilators (Tsunami,
Spectra-Physics Lasers) are temporally synchronized and collinearly combined into a
laser-scanning inverted microscope (FV300+IX71, Olympus). Pump and Stokes lasers
were tuned to 707 nm (14140 cm-1) and 885 nm (11300 cm-1), respectively, to be in
resonance with the CH2 symmetric stretch vibration at 2840 cm-1. Combined beams were
focused into the specimen through a 60x water immersion objective with a 1.2 numerical
aperture (UPlanApo/IR, Olympus). The forward CARS signal was collected by an air
condenser with a 0.55 numerical aperture, transmitted through a 600/65 nm bandpass
filter, and detected by a PMT (H7422-40, Hamamatsu). Average acquisition time for a
512 x 512 pixels CARS image was 1.12 second, and the combined Stokes and pump laser
power at the specimen was kept constant at 40 mW. Following CARS imaging, the
Stokes beam was blocked and the pump laser induced Raman scattering signal was
directed toward the spectrometer (Shamrock SR-303i-A, Andor Technology), which was
mounted to the side port of the microscope, to permit spectral analysis from 900 cm-1 to
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3100 cm-1. The spectrometer pinhole was 50-μm in diameter, which provides an axial
resolution of about 4 μm. The lateral resolution was about 0.4 µm. Each Raman spectrum
was acquired in 10 seconds, and pump laser power at the specimen was maintained at 15
mW. No tissue damage was observed.
To determine the location of the ApM and BaM, we first adjusted the focus to the
equatorial plane of an acinus based on the CARS image (see Figure 3.3A). We then
zoomed into the apical site of the acinus by CARS (see Figure 3.3B) and positioned the
laser focus for Raman measurement on the most apical pole of certain epithelial cells in
the acinus (e.g. the location indicated by the magenta circle in Figure 3.3B). We then
moved the focus to the basal site of the acinus (see Figure 3.3C) and positioned the focus
for Raman measurement on any location on the BaM of certain epithelial cells of the
acinus (e.g. the location indicated by the blue circle in Figure 3.3C).
For Raman analysis, two spectra were taken, one from the cell (membrane,
cytoplasm, or nucleus) and the other from the glass. The glass contribution was removed
by first scaling the glass profile to make its intensity of the peak-free region (2000-2600
cm-1) the same as that of the cell profile, and then subtracting this modified glass profile
from the cell profile. The fluorescence background in the resultant Raman spectrum was
fitted by a 4th order polynomial function and further removed. The 4th order polynomial
fit was achieved by choosing six points in the spectrum lacking any spectral features. For
a better comparison of spectral patterns, each Raman spectrum was then normalized by
dividing by the peak intensity of the band around 2935 cm-1 over the spectral range 2770
- 3070 cm-1. Then, the normalized Raman spectra were least-squares fitted as a sum of
seven Lorentzian bands [330].
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Figure 3.3 Label-free analysis of lipids in polarized mammary acini. (A)
CARS image of a mammary acinus with apical and basal poles. (B) CARS
image of the orange square in A shown at higher magnification. Crosses
within purple and black circles, which indicate ApM and cytoplasmic regions
of the cell respectively, are the positions for confocal Raman spectral
measurement. (C) CARS image of the blue square in A shown at higher
magnification. Crosses within blue and green circles, which indicate BaM and
nucleus regions of the cell respectively, are the positions for confocal Raman
spectral measurement. (D) Normalized Raman spectra of regions within ApM
(purple line), BaM (blue line), cytoplasm (Cyto, black line), and nucleus (Nuc,
green line). (E-H) Lorentzian curve fitting for Raman spectra of ApM, BaM,
Cyto, and Nuc. Original spectra are shown in the same color as in D. The
Lorentzian fitting curves are shown in green. The areas under Raman bands
around 2850 cm-1 and 2885 cm-1 are highlighted with green stripes. The
cumulative fitted curves are shown in orange. (I) Ratio A2885/A2850 (R) for
ApM and BaM (R for Cyto equals 1.56, and R for Nuc equals 4.11). (J)
Fluorescence image of the mammary acinus in A labeled for apical polarity
marker ZO-1(red) and DNA (DAPI, blue; nine nuclei are seen in this focal
plane). Scale bars, 10 µm.
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7

𝐼𝑅𝑎𝑚𝑎𝑛 (𝑤) = ∑
𝑗=1

2𝐴𝑗
𝛤𝑗
𝜋 4(𝑤 − 𝛺𝑗 )2 + 𝛤𝑗 2

where w is the wavenumber, Aj is the area under the jth band, j is the width and j is the
center wavenumber of the jth band. Peak wavenumbers and widths for curve fitting are
listed in Table 3.1. The corresponding assignments of Raman peaks are listed in Table
3.2 [320, 336].
Table 3.1 Curve fitting parameters. The parameters of the seven Lorentzian bands
used to fit the 2770 – 3070 cm-1 regions of all Raman spectra.
Peak center (Ωj, cm-1)
Peak width (Γj, cm-1)
2845-2855
2856.5-2870
2875-2888
2885-2910
2930-2945
2958-2972
2980-3000

13.5
23.0
22.0
32.0
47.0
30.0
32.0

For Raman analysis of membrane lipid ordering, CARS microscopy was first used
to visualize cell membranes of live mammary acini. Details about how to determine the
location of the ApM and BaM can be found in the Supplemental Materials and Methods.
The intense bands around 2850 cm-1 and 2885 cm-1 have been assigned to symmetric and
asymmetric CH2 stretching, respectively. The band around 2885 cm-1 is markedly
enhanced by Fermi resonance in ordered lipid packing, whereas the band around 2850
cm-1 is not affected by structural changes of the lipid hydrocarbon chains [317, 318, 336].
Thus, the degree of lipid ordering can be represented by the ratio between the areas under
Raman bands at 2885 cm-1 (A2885) and 2850 cm-1 (A2850), A2885/A2850 (R) [317, 318, 336].
ApM_R (or BaM_R) was the degree of lipid ordering of ApM (or of BaM). A
ratio ApM_R/BaM_R was defined to represent the relative degree of lipid ordering of
ApM compared with that of BaM. To illustrate the ability of the ratio ApM_R/BaM_R to

78
Table 3.2 Assignments of Raman peaks.
Assignments
Raman shift (cm-1)
Protein

Lipid

symmetric CH2 stretching

2850
2860

vibration
Fermi resonance between
the asymmetric CH2

2882

stretching mode
asymmetric CH2 stretching

2902

symmetric CH2 stretching

2936

asymmetric CH3 stretching

vibrations
vibration

2967
2986

vibration
Fermi resonance between
the asymmetric CH2
stretching mode
symmetric CH3 stretching
vibration
asymmetric CH3 stretching

asymmetric CH3 stretching

vibration
asymmetric CH3 stretching

vibrations

vibration

differentiate between P and Non-P mammary acini, a ROC curve was generated by
plotting sensitivity vs. (1-specificity) and the AUC was calculated. Based on the ROC
curve, the best cutoff of ApM_R/BaM_R was determined.

3.2.4

Statistical Analysis

Student’s t test was used to (1) compare the degree of lipid ordering (R) of ApM
and that of BaM for P and Non-P mammary acini, respectively, (2) compare the ratio
ApM_R/BaM_R of P mammary acini and that of Non-P mammary acini, and (3)
compare the ApM_R (or BaM_R) of P mammary acini and that of Non-P mammary acini.
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p < 0.05 was considered statistically significant. The exact p values are shown in the
corresponding figure captions.

3.3

Results and Discussion

As CARS permits selective imaging of lipid-rich structures, it was used to
visualize the ApM and BaM in the equatorial plane of live mammary acini. Substantial
CARS signals arose from the lipid-rich ApM and BaM of the mammary acinus, whereas
weak CARS signals came from the lipid-poor cell nucleus (Figure 3.3A-C). This strong
contrast easily distinguished, in a label-free manner, the different compartments of
individual cells that form the single-layered epithelium. Considerable CARS signals also
arose from the cytoplasmic space, possibly due to lipid-rich organelles such as
endothelium reticulum, LDs and mitochondria. An important characteristic of the
morphogenesis of acinar structures is the narrower width of the apical pole compared to
the basal pole [313]. This characteristic was clearly outlined by CARS (Figure 3.3C).
Confocal Raman microspectroscopy was further used to analyze lipid phases of ApM and
BaM.
As shown in Figure 3.4, both ApM and BaM are present within the axial
resolution of confocal Raman microspectroscopy (~4µm). Although the fingerprint
regions on Raman spectra of ApM and BaM (Figure 3.5) did not show clear difference
due to the low signal to noise ratio, the C-H stretching regions were very distinct (Figure
3.3D), indicating unique compositions of these cellular compartments. Moreover, based
on the Lorentzian curve fitting, the degrees of lipid ordering represented by the ratio
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Figure 3.4 Depth-resolved CARS images of the apical and basal poles of a
mammary acinus. Arrowheads indicate the ApM in A and BaM in B. Scale
bars, 10 µm.
between the areas under Raman bands at 2885 cm-1 (A2885) and at 2850 cm-1
(A2850), A2885/A2850 (R), were different among ApM, BaM, cytoplasm and nucleus (Figure
3.3E-H). In particular, R was much higher in ApM relative to BaM in the majority of P
acini (n = 40) (Figure 3.3I). The polarized status was confirmed by the apical location of
ZO-1 (Figure 3.3J). These results indicate that in the 3D acini, we are able to obtain
distinctive Raman spectra from ApM and BaM, which are visualized by CARS.
Moreover, the degree of lipid ordering, quantified by the ratio A2885/A2850 (R), is different
between ApM and BaM.
In order to induce a significant loss of apical polarity in the acini population, 10day 3D cultures were incubated with 1.5 mM EGTA as shown previously [293]. Note
that EGTA does not affect membrane lipid ordering (R) in mammary epithelial cells (S1
cells in 3D culture on day 1) before apical polarity has been formed (Figure 3.6). Raman
spectra were then recorded for the nonpolarized (Non-P) mammary acini (i.e., with
nonapically concentrated ZO-1 staining) from EGTA-treated cultures (usually more than
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90% of acini are not apically polarized after EGTA treatment) and from control cultures
(usually ~25% of acini are not apically polarized in routine 3D culture) (Figure 3.7).
Breast epithelial cells treated with EGTA became round due to the loosening of cell-cell

Figure 3.5 Raman spectra (900 – 1800 cm-1) of ApM, BaM, cytoplasm, and
nucleus of the acinus shown in Figure 3.3A.

Figure 3.6 CARS images and membrane lipid ordering (R) of S1 cells in 3D
culture before apical polarity has formed. EGTA was added on day 1 of 3D
culture. Analysis was performed before and after 24h EGTA treatment.
Control dishes were analyzed at the same time points. n = 5 cells. No
statistical difference was found among the four compared groups (one-way
ANOVA). Crosses indicate the locations for Raman spectral analysis. Scale
bars, 10 µm.
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contacts, which leads to acini with bumpy outer contour (Figure 3.7B). This morphology
was in contrast with the control population in which acini usually had a smooth
circumference regardless of their polarity status (compare Figure 3.3A to Figure 3.7A).
Yet, lipid ordering (R) was consistently lower in ApM compared to BaM in Non-P
mammary acini regardless of the change in cell shape, indicating that disruption of apical
polarity per see is sufficient to show the reorganization of lipids (Figure 3.7).
To confirm that lipid ordering (R) was statistically different between ApM and
BaM in both P and Non-P mammary acini, it was analyzed in 40 P and 40 Non-P
mammary acini. Indeed lipid ordering was significantly higher in ApM compared to BaM
for P mammary acini; whereas it was significantly lower in ApM compared to BaM for
Non-P mammary acini (Figure 3.8A). The result for P mammary acini is consistent with
chromatography analysis of the lipid composition of polarized intestinal cells that shows
more ordered lipids within ApM than within BaM [303, 304, 337]. In addition, lipid
ordering (R) was significantly higher for the ApM of P mammary acini compared to that
of Non-P mammary acini, and significantly lower for the BaM of P mammary acini
compared to that of Non-P mammary acini. The alterations in membrane lipid ordering in
Non-P mammary acini compared to P mammary acini might be due to the disruption of
tight junction, which leads to improper sorting of membrane lipids including cholesterol
and sphingolipids. Although the specific lipid compositions of ApM and BaM remain to
be investigated, the lipid ordering shows potential to distinguish P and Non-P mammary
acini (Figure 3.8A). In order to differentiate P and Non-P mammary acini with both high
sensitivity and specificity, the lipid ordering ratio, ApM_R/BaM_R, was analyzed. This
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Figure 3.7 Label-free analysis of lipids in nonpolarized mammary acini.
Shown are the CARS image, the Raman spectra of ApM and BaM with
Lorentzian fitting, the ratio A2885/A2850 (R) for ApM and BaM, and
immunofluorescence labeling for ZO-1(red; arrows indicate the presence of
ZO-1 at the basal side of the acinus) for a nonpolarized (Non-P) mammary
acinus in the control group (A) and a Non-P mammary acinus in the EGTAtreated group (B). Nuclei are counterstained with DAPI (blue). Scale bars,10
µm.

ratio represents the relative degree of lipid ordering of ApM (ApM_R) compared with
that of BaM (BaM_R). Raman scans from different ApM and BaM locations inside an
acinus (P or Non-P acinus) did not produce statistically different lipid ordering ratios
(Figure 3.9). Importantly, the lipid ordering ratio was significantly higher for P mammary
acini compared to Non-P mammary acini with much smaller p value than that obtained
from the comparison of these same populations based solely on ApM_R or on BaM_R
(Figure 3.8B). This result suggests that P and Non-P mammary acini can be distinguished
with higher statistical significance when using the lipid ordering ratio compared to the
ratio R for the ApM or for the BaM.
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Figure 3.8 Distinction between ApM and BaM in polarized and nonpolarized
acini. (A) Comparison of the ratio A2885/A2850 (R) in ApM and BaM
regions for both polarized (P) mammary acini and nonpolarized (Non-P)
mammary acini. (B) Comparison of the relative lipid ordering ratio
ApM_R/BaM_R in P mammary acini and Non-P mammary acini. (Student's
t-test, * p < 5.0E-5, ** p < 1.0E-5, *** p = 4.0E-20, n=40 acini).
The ratio of the symmetric C-H stretching mode intensities (peak height), I2885/I2850 (R’),
is a well accepted representation of the packing order of acyl chains [317, 318, 320, 338].
However, multiple peaks overlap within the C-H stretching region, which may cause
inaccuracy when using peak height to calculate lipid ordering. Therefore in the results
presented above we have used Lorentian fitting to obtain peak areas for each Raman
bands and we have represented lipid ordering by the ratio of the areas R. The fitting
results including parameters, statistics, and residuals can be found in Table 3.3 and Figure
3.10. In order to compare our results with previous work that used R’ [318, 338], we also
calculated R’ for the same 40 P and 40 Non-P acini used for R calculation in Figure 3.8.
R’ fell mainly between 1.5 and 2 (for liquid R’ equals 0.7, and for crystal it equals 2.2
[318, 338]) and showed the same trends as with R (compare Figure 3.8 to Figure 3.11).
However, the p values obtained from R’ calculations were bigger than those obtained
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from R calculations, suggesting that R would perform better in distinguishing P and NonP acini.

Figure 3.9 Reproducibility of ApM_R/BaM_R measurement. For both P and
Non- P acini, ApM_R/BaM_R ratios were obtained based on three Raman
scans performed at 3 different locations (labeled as ApM1, ApM2, ApM3) of
ApM. No statistical significance was found using ANOVA test.

Table 3.3 An example of fitted curve parameters (peak center, peak width, and area under
peak) and statistics (reduced Chi-square and adj. R-square). The statistics reflect the
goodness of fit. The numbers in parentheses are the corresponding SDs.
Peak center
Peak width
Area under
Statistics
(Ωj, cm-1)
(Γj, cm-1)
peak (a.u.)
2855.0 (1.4)
13.5
3.3 (1.0)
Reduced Chi2866.9 (3.0)
23.0
6.5 (1.2)
Adj. R-Square:
2884.4 (1.7)
22.0
10.0 (1.7)
Square:
2900.1 (2.1)
32.0
16.3 (1.9)
0.992
2935.4 (0.9)
47.0
62.0 (1.8)
8.6E-4
2960.0 (2.2)
30.0
9.7 (1.6)
2986.5 (1.3)
32.0
11.6 (0.9)

To determine the ability of the lipid ordering ratio, ApM_R/BaM_R, to
distinguish P from Non-P mammary acini, the histogram of the number of acini was
plotted as a function of this ratio (Figure 3.12). The plots for P and Non-P mammary
acini were assigned a red and blue color, respectively, and were fitted with normal
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distribution curves. An overlap between plots indicated that proper cutoff was required in
order to distinguish P from Non-P mammary acini with both high sensitivity and

Figure 3.10 Residuals of the Lorentzian fittings for Figure 3.3 and Figure
3.7A-B.

Figure 3.11 Distinction between ApM and BaM in polarized (P) and
nonpolarized (Non-P) acini, using the ratios I2885/I2850 (R’) and
ApM_R’/BaM_R’. (A) Comparison of the ratio I2885/I2850 (R’) in ApM and
BaM for both P mammary acini and Non-P mammary acini. (B) Comparison
of the ratio ApM_R’/BaM_R’ in P mammary acini and Non-P mammary
acini. (Student's t-test, * p < 0.05, ** p < 5.0E-4, *** p = 6.1E-6, n=40 acini).
specificity. A ROC curve was built to illustrate the tradeoff between sensitivity and
specificity by plotting the true-positive rate against the false-positive rate for the different
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possible cutoffs of the lipid ordering ratio. The closer the curve comes to the 45-degree
diagonal (shown as a thin black line in Figure 3.12B) the less accurate the diagnostic test.
The big AUC (=0.98) clearly demonstrated the ability of the lipid ordering ratio to
accurately differentiate P from Non-P mammary acini (Figure 3.12B). More importantly,
the ROC curve provided a way to obtain the desired degree of sensitivity at the cost of
specificity. Here, both high sensitivity (=0.925) and specificity (=0.925) were gained with
a cutoff of 1.0 (lipid ordering ratio = 1.0). Therefore, it is possible to quantitatively and
accurately distinguish P from Non-P mammary acini by the lipid ordering ratio with both
high sensitivity and high specificity.

Figure 3.12 Sensitivity and specificity of the relative lipid ordering ratio in
identifying polarized and nonpolarized acini. (A) Histogram plot of the
number of acini as a function of the lipid ordering ratio (Blue: nonpolarized
(Non-P) mammary acini, Red: polarized (P) mammary acini). (B) ROC curve
illustrating the ability of lipid ordering ratio to distinguish P and Non-P
mammary acini (green line). The ROC curve of two indistinguishable
populations, represented by the black line, is included for comparison.

As an application of the label-free approach developed above to measure polarity
status, disruption of apical polarity was tracked over time in mammary acini undergoing
AA treatment. Dietary fatty acids have been associated with breast cancer development
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[42, 339-343]. Particularly, high dietary intake of ω6 PUFAs has been associated with
increased breast cancer risk [344]. Moreover, certain dietary interventions with fatty
acids were shown to lead to rapid and potentially beneficial changes in ω3/ω6 PUFA
ratio in the serum and breast adipose tissue [345, 346]. So far it is unknown whether ω6
PUFA could participate in the initiation stage of breast neoplasia by disrupting apical
polarity. The impact of AA on apical polarity was assessed in series of eight live acini
before and after treatment with 60 M AA. CARS images of the same mammary acini
were taken before and after a 4-day AA treatment and the status of apical polarity was
evaluated based on lipid ordering ratio (Figure 3.13A, 3.14). After excluding the acini
that were nonpolarized already before AA treatment, a statistically significant loss of
apical polarity (~30% of the population studied) was measured in AA-treated acini
(Figure 3.13B). In contrast, examination of the apical location of tight junction protein
ZO-1 by immunostaining in the same sets of samples and in 100 acini randomly chosen
in each experiment, failed to reveal a statistically significant loss of apical polarity in
AA-treated acini population (Figure 3.13C, 3.15).
The results shown in Figure 3.13 demonstrate that although immunostaining of
tight junction proteins has been commonly used to determine the status of apical polarity
[293, 313, 315], it is not very effective to detect significant loss of apical polarity induced
by dietary factors in a small portion of the acini population. This ineffectiveness of
immunostaining method is largely due to the variation between different cultures, given
that the percentage of P mammary acini in control cultures varies from 60% to 80% [293,
313, 315].
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Figure 3.13 Measurements of the polarity status in acini before and after
treatment with ω6 fatty acid. Acini were incubated with either ethanol vehicle
or 60 µM AA from day 8 to 12 of 3D culture. (A) Status of apical polarity
(polarized, P or nonpolarized, Non-P) based on the lipid ordering ratio
(ApM_R/BaM_R, number indicated in parenthesis; R = A2885/A2850) for the
same group of acini before and after AA treatment as measured by the Raman
scattering-based method. (B) Percentage of acini that have lost apical polarity
in the control and AA-treated groups at day 12 (after treatment with vehicle or
with AA) compared to day 8 (before treatment) detected by the Raman
scattering-based method (*p value=0.0066, n=3 sets of 8 acini). (C)
Percentage of acini with ZO-1 apically localized in vehicle control and AAtreated groups at day 12 of 3D culture (using the sample sets analyzed in B).
Scale bar, 5 µm.

By tracking the status of apical polarity for the same live acini before and after treatment
with the Raman method, we are able to take into account only the acini that are apically
polarized before treatment and then readily measure how many of them lose apical
polarity. Thus, our label-free Raman analysis measures a true effect of the treatment on
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apical polarity by discarding false positives, that is, the acini that would not have been
apically polarized from the start.

Figure 3.14 Immunofluorescence images of AA-treated mammary acini.
Immunostaining for ZO-1 (red) and labeling for DNA (DAPI, blue) in acini
following treatment with AA shown in Fig. 5A. Scale bar, 5 µm.

Figure 3.15 Blind scoring of ZO-1 localization in control and AA-treated acini
populations. Acini in control and 60 µM AA-treated groups were fixed and
immunolabeled for ZO-1 in three independent experiments (the same ones
shown in Fig. 5). Here, at least 100 acini were randomly chosen and scored
(ZO-1 staining apically localized or not apically localized) per experiment and
results were analyzed by Student’s t-test.

To understand the origin of reduced lipid ordering in Non-P acini, we further
studied how AA treatment might affect the tight junction complex. It is possible that the
effect of AA might only encompass ZO-1, leaving the rest of the tight junction intact. To
rule out this possibility, the effect of AA was studied not only on ZO-1 but also on ZO-2,
another core tight junction protein that links transmembrane proteins to cytoplasmic
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Figure 3.16 Distribution of apical polarity-related proteins in polarized (P) and
nonpolarized (Non-P) acini. Dual staining for tight junction core proteins ZO1 and ZO-2 (A), ZO-1 and cytoskeleton component actin (B), and
immunolabeling for apical polarity organizer hScrib (C) in P mammary acini
in the control group (vehicle, Veh) and Non-P mammary acini in ω6 AAtreated group. Cell nuclei were labeled with DAPI (blue color). (D)
Histograms of the percentages of acini with apically located ZO-1 (p =
0.0167), ZO-2 (p = 0.0026), hScrib (p = 0.0347) and actin (p = 0.0043), (n=3,
V: Veh, A: AA). * p < 0.05; ** p < 0.01. Scale bar, 5 µm.

components of the junctional complex and the cytoskeleton [347-349]. Immunostaining
performed in a new set of experiments revealed that the two tight junction core proteins
ZO-1 and ZO-2 colocalized in more than 90% of the cases when apically located and
were significantly mislocalized upon AA treatment (Figure 3.16A) but did not overlap
when away from the apical pole, suggesting that AA affects the tight junction complex
globally. ZO-1 is the main protein that stabilizes the tight junction to the actin
cytoskeleton in cells [347, 349, 350], therefore a severe disruption of the tight junction
complex should be associated with the reorganization of the cytoskeleton. In cells that
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had apically polarized ZO-1, staining for polymerized actin was strongest at the apical
side of the cells (Figure 3.16B). This is expected since the actin cytoskeleton serves as a
framework to which tight junction complexes can bind and be secured in place [349].
However, in the cells that had mislocalized ZO-1, the actin cytoskeleton was diffuse
(Figure 3.16B), in agreement with a disruption of the tight junction complex. Tumor
suppressor hScrib [312] plays a critical role during the initial formation of the tight
junction complex [351] and disruption of tight junctions might perturb its function. In
control acini, hScrib was located at the apical side with some lateral positioning, as
shown by immunostaining. However, in acini treated with ω6 AA, hScrib became
mislocalized as revealed by a diffuse staining pattern (Figure 3.16C). Although the
immunostaining method cannot always detect a significant difference between control
and treated groups (Figure 3.13C, 3.14), there have been some instances in which the AA
treatment induces statistically significant loss of apically located ZO-1, ZO-2, hScrib, and
actin, as shown in Figure 3.16D. These observations suggest that AA profoundly affects
apical polarity, including the integrity of hScrib tumor suppressor localization.
Specifically, they indicate that AA causes acinar cells to lose apical organization via a
disruption of the tight junction complex, because two of the tight junction core proteins
redistribute away from the apical pole and tight junction anchorage to the actin filament
network is destabilized. Considering the key role of actin filaments in maintaining the
integrity of cell membranes, cytoskeleton disruption is consistent with the reduced lipid
ordering in the ApM as detected by the Raman analysis. Therefore the lipid ordering ratio
is a powerful way to measure modifications in tissue polarity, and thus, tissue
homeostasis in live epithelia.
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Our technique can be potentially used, in association with the breast cell model,
as a screening method of risk factors for breast cancer as well as a screening method for
chemopreventive agents in a similar way as what scientists are starting to do with cancer
cells. In the latter case, cancer cells placed in 3D culture form tumor nodules that are then
treated with potential anticancer drugs to test the cytotoxicity of these agents. In our
study we are working with non-neoplastic cells based on increasing evidence from cell
culture and patient studies that loss of apical polarity is a very early sign of a
preneoplastic change [293]. There are currently no ways to test for dietary or chemical
compounds that could act as agents to initiate and prevent the development of breast
tumors. We are proposing that our apical polarity measurement method in 3D cell culture
of non-neoplastic cells would permit accurate screening of deleterious factors for breast
health (that would induce loss of apical polarity) and also preventive factors (based on the
reestablishment of apical polarity by these factors or their effect to prevent apical polarity
loss normally induced by other factors). The possibility of live cell detection with Raman
technology will permit the study of sequential effects of factors of interest, e.g., to assess
whether factor B restores apical polarity previously altered by factor A.
We have demonstrated that a Raman scattering based platform can be used to
provide label-free determination of apical polarity of live mammary acini in 3D culture.
In this method the lipid configurations within apical and BaM are measured by highspeed CARS imaging integrated with confocal Raman analysis. Notably, the derived ratio
of the degree of lipid ordering appears superior to immunofluorescence-based analysis of
fixed samples to determine the presence or disruption of apical polarity. This method has
enabled us to quantify, with high sensitivity and specificity, the percentage of acini that
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lose apical polarity due to the effect of AA, a risk factor for breast cancer development.
The proposed method provides an unprecedented label-free screening platform for rapid
identification of risk factors that initiate the very early stage of epithelial neoplasia.
Moreover, the use of the membrane lipid phase as readout to assess polarity should be
applicable to other types of epithelia where over 90% of cancers originate. Indeed
polarity is a common feature of the homeostasis of such tissues and all studies of early
changes in epithelial neoplasms so far report polarity loss.
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CHAPTER 4. LABEL-FREE IDENTIFICATION OF MAMMARY ADENOMA AND
ADENOCARCINOMA BY COHERENT ANTI-STOKES RAMAN SCATTERING
AND SUM FREQUENCY GENERATION IMAGING

A portion of the work presented in this chapter was published in Laser & Photonics
Reviews [217]. Reprinted with permission from [217]. Copyright © 1999-2013 John
Wiley & Sons, Inc.
Intact and unstained mammary tissues were examined by a multimodal NLO
imaging system that allows CARS imaging of lipid-rich structures and SFG imaging of
type I collagen fibrils. The CARS signals arising from cell membranes and cytoplasmic
LDs allowed the identification of tumor cells, adipocytes, and endothelial cells.
Simultaneous CARS and SFG imaging enabled direct 3D visualization of cell
arrangement and ECM organization, but without the requirement for labeling. Epithelial
cells that form a single row on the innermost part of the duct were visualized in normal
mammary glands. In mammary adenomas, abundant wavy collagen fibrils formed a
smooth outer contour to concentrically wrap the small cluster of tumor cells. In mammary
adenocarcinomas, epithelial cells showed a ragged contour without an organized
concentric wrap of collagen around them. These results were verified by histological
analysis.

Quantitative

analysis

of

collagen density indicated

that mammary

adenocarcinomas had much less collagen density surrounding tumor mass than mammary
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adenomas. Taken together, these findings suggest that multimodal CARS/SFG imaging
could potentially be an intraoperative image-guided tool for assessing tumor margins
during breast cancer surgery
4.1

Introduction

Breast cancer is the most common form of cancer in women, except for nonmelanoma skin cancer, and it is also the leading overall cause of cancer death in women
between the ages of 20 and 59 [1, 352]. Fortunately, approximately 90% of initial breast
cancer cases are diagnosed as a localized or locoregional disease, which can be attributed
to the increased use of screening mammography [353]. Considering the negative impact
of mastectomy on cosmesis and associated psychological issues of breast cancer patients
[354], and the equivalent effectiveness of mastectomy and lumpectomy [355, 356], the
National Institutes of Health has suggested lumpectomy as a primary treatment option in
the majority of women with early-stage breast cancers [357]. Theoretically, nonhematological cancers can be cured if entirely removed by surgery, but this is not always
possible because a single cancer cell, invisible to the naked eye, can re-grow into a new
tumor. In order to define negative margins that are free of any cancer cells adjacent to the
boundary of the tissue resection, pathologists need to examine the surgical specimen to
determine if a margin of healthy tissue is present. As a result, about half of the patients
undergoing lumpectomy have to suffer repeated surgical procedures called re-excisions
[358]. Studies have shown that the risk of local recurrence and distant metastasis after
lumpectomy is positively associated with the appearance of positive margins after the
first surgery and the numbers of re-excision lumpectomies [359, 360]. Thus, accurately
attaining negative margins at the first surgical procedure is the optimal outcome of
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lumpectomy. To assist in a complete resection of adenocarcinomas with negative margins
in a single surgical procedure, we need an efficient intraoperative image-guided tool that
can distinguish normal breast tissues from malignant tumor tissues [361-364].
Although histopathology has been the gold standard for cancer diagnosis, it
cannot be used as an intraoperative image-guided diagnostic tool because histology
requires time-consuming sample preparation, and it cannot provide 3D and real-time
information about tissue architecture and organization in the natural state. Recently,
medical imaging techniques, such as ultrasound [365], MRI [366] and radiofrequency
spectroscopy [367], have been used as image-guide intervention methods in cancer
surgery. However, all these imaging techniques only allow visualization of tissue
anatomy with the resolution of ~1mm, which is not sufficient for accurate determination
of tumor margins during the surgical phase. In addition to those clinical and diagnostic
imaging techniques currently in use, optical imaging and spectroscopy are gradually
becoming popular in the development of novel tumor diagnostic techniques. For example,
OCT allows cross-sectional imaging of breast cancer in surgery with an endoscope [368,
369]. Raman spectroscopy has been employed to diagnose epithelial pre-malignant
lesions and cancers based on chemical composition [370]. Confocal reflectance
microscopy [371] and elastic scattering spectroscopy [372] have also been used for
cancer diagnosis in clinical studies. However, their limited resolution or limited
specificity hampers identification of the organization and composition of normal or
disease states of mammary glands, which would be vital to the definition of negative
boundaries. Therefore, the intraoperative image-guided tool needs to be an imaging
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technique that enables visualization of cellular and subcellular structures with high
resolution.
During the past two decades, NLO imaging has opened a new window for cancer
imaging [373]. In addition to submicron spatial resolution, NLO imaging allows 3D
imaging of tissue architecture with large penetration depths, which cannot be attained
using conventional histological techniques or confocal fluorescence microscopy.
Collective studies have shown that differences in morphology and metabolic activity
between malignant and non-malignant epithelial cells can be delineated by TPEF imaging
of endogenous fluorophores, such as NAD(P)H and FAD [374, 375]. A distinct
advantage of this method is that it avoids the need for any exogenous labeling agents,
thus eliminating toxicity and safety concerns related to their use. However, based solely
on the fluorescence signal from endogenous fluorophores, clear images of tumor cell
structures are difficult to produce. In addition, TPEF is often combined with SHG
imaging that visualizes type I collagen fibrils within tumor tissues, a major component of
ECM [376].
To visualize biological molecules that cannot bear fluorescent labeling, CARS
microscopy has been developed for high-speed vibrational imaging of lipid-rich
structures, such as cellular membranes, myelin sheath, and cytoplasmic LDs [217]. More
recently, multimodality imaging on a CARS microscope has been realized by
implementation of SFG and TPEF using the same picoseconds laser sources [217]. The
application of CARS microscopy to cancer imaging is emerging. Le et al. have
demonstrated that CARS microscopy is able to visualize lipid-rich tumor cells in vitro
and in mammary tissues [221, 377]. Evans et al. have applied CARS microscopy to
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vibrational imaging of brain tumor [378]. Nevertheless, the ability of CARS microscopy
to differentiate adenomas from adenocarcinomas has not been demonstrated. Additionally,
the advantages of integrating CARS and SFG for cancer detection have not been explored.
In this paper, we investigated whether multimodal CARS/SFG imaging could be
used to characterize the features of unstained normal mammary gland, adenomas and
adenocarcinomas in a methylnitrosourea (MNU)-treated female Sprague-Dawley rat
model. Tumors induced in rats by administration of chemical carcinogens, such as MNU,
have the potential to be examined during the multi-step process of carcinogenesis,
including initiation, promotion, and progression [379, 380]. Here, we observed
substantial CARS signals arising from the lipid-rich cell membranes and cytoplasmic
LDs, but weak CARS signals from the lipid-poor cell nuclei. Thus, CARS imaging
enabled us to identify various cell types, such as tumor cells, adipocytes, and endothelial
cells, based on cell morphology and cytoplasm/nucleus ratio. Moreover, simultaneous
CARS and SFG imaging enabled direct 3D visualization of cell arrangement and ECM
organization without labeling. These results were verified by corresponding staining and
standard histological analysis. Based on the morphology and 3D arrangement of
epithelial cells and organization of collagen fibrils, we demonstrated that CARS/SFG
imaging was able to accurately identify the normal mammary gland and distinguish
between adenomas and adenocarcinomas. These findings suggest that CARS/SFG
imaging could become an intraoperative image-guided tool for assessing tumor margins
during breast cancer surgery.

100
4.2
4.2.1

Experimental Section

Animal Model and Tissue Specimens

Outbred female Sprague-Dawley rats were placed on a rat chow diet (Harlan Tech,
Indianapolis, IN) containing 3.30 kcal/g of metabolizable energy. Rats received the
carcinogen MNU or a control 0.9% saline injection. Tissue specimens for CARS/SFG
imaging were flash frozen in liquid nitrogen and stored at -80 C. Prior to imaging, tissue
samples were briefly thawed at room temperature and fixed in 10% neutral-buffered
formalin. All animal experiments were done with the approval of the Purdue Animal Care
and Use Committee.

4.2.2

Histological Analysis

Mammary glands and tumor tissues were fixed in a solution of 10% neutralbuffered formalin. After fixation, tissues were processed and embedded in paraffin blocks.
Tissue sections of 5 µm thickness were prepared and stained with hematoxylin-eosin.
Mammary tumors from MNU-injected animals were classified as adenomas and
adenocarcinomas based on gross morphology by a board certified pathologist. Normal
mammary tissue from saline-injected animals was verified as free of any lesions.
Histology images were acquired using a Nikon Eclipse E400 microscope (Nikon Corp.,
Tokyo, Japan) equipped with air objectives and a Spot Insight camera (Diagnostic
Instrument, Inc., Sterling Heights, MI).
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4.2.3

CARS/SFG Imaging System

Figure 4.1 Multimodal NLO imaging methods and setup. (A) Energy diagram
of NLO processes including CARS, SFG, and TPEF. (B) Schematic of a NLO
microscope which combines CARS, SFG, and TPEF on the same platform.
Inset window shows the simplified light path. DM: dichroic mirror, M: mirror.
(C) Emission spectra of SFG signals from collagen fibrils (blue); TPEF
signals from Hoechst 33342-labeled nuclei (green); and CARS signals from
LDs (red).

A multimodal NLO microscope which allows CARS, SFG, and TPEF imaging on
a single platform (Figure 4.1B) has been previously described [217]. The energy
diagrams of CARS, SFG, and TPEF are shown in Figure 4.1A. The details has been
described in previous chapters.
Microspectroscopy analysis of mammary tissue components was carried out by
using a spectrometer (Sharmrock 303i, Andor Technology, Belfast, Ireland) equipped
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with an electron multiplying CCD (EM-CCD, Newton-970N-BV, Andor), installed at the
back port of the microscope, and externally triggered by the confocal scanner. In this
experiment, we first acquired an image, and then focused the light into a pixel of interest
by the point-scan mode. The point-scan action triggered the spectrometer to record a
spectrum of the NLO signals arising from the focal region (Figure 4.1C).

4.2.4

Imaging Conditions

No sample preparation was necessary before imaging the excised mammary
tissues. A glass-bottom chamber containing tissues submerged in 1x PBS was placed on
the microscope for imaging at room temperature. For CARS, SFG, and TPEF imaging of
fixed tissues, the average powers of the pump and Stokes laser beams were attenuated by
using neutral-density filter wheels to 40 mW and 20 mW at the sample when using the
20x objective, and 20 mW and 20 mW at the sample when using the 60x objective. For
CARS and SFG imaging of histology slides, the average powers of the pump and Stokes
laser beams were attenuated to 10 mW and 5 mW at the sample using the 20x objective.
There was no noticeable photodamage to the samples throughout the imaging processes.
To visualize the tumor architectures with 3D cellular and subcellular resolution,
we directly placed tissues of different thickness around 5 mm on a glass surface such that
a relatively flat tissue surface faces the 60x water immersion objective on an inverted
microscope. When the beating frequency was set to the specified 2840 cm-1, substantial
CARS signals arising from the lipid-rich structures were observed.
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4.2.5

Quantitative Analysis of Collagen Density Surrounding Tumor Mass

An analysis volume was defined with the dimensions of 250 µm (x) × 250 µm (y)
× 30 µm (z), with z = 0 being the tumor mass and collagen interface. For each analysis
volume, 31 frames along the z-axis with a fixed step size of 1 µm were acquired. Six
different volumes were evaluated, and the total SFG intensity from 186 frames (6 × 31
frames) was used to infer the mammary stromal collagen density surrounding tumor mass.
The laser power at the sample and the high voltage of the PMT were kept constant for all
measurements.

4.3
4.3.1

Results

Significant Components of Mammary Tissues Visualized with Label-free
CARS/SFG Imaging

Since CARS is sensitive to lipids, which are a main component of the cytoplasmic
LDs, cell membranes, and intracellular membranes, we used CARS to depict morphology
of various cell types in mammary tissues. We observed substantial CARS signals arising
from the cell membranes and cytoplasmic LDs, but only weak CARS signals from the
lipid-poor cell nuclei (Figure 4.2A), a contrast indicating significantly enhanced
visualization of cell morphology. Thus, CARS images enabled the identification of
various cell types based on cell morphology and nucleus-cytoplasm ratio. For instance,
mammary tumor cells were identified by a round shape and a large nucleus-cytoplasm
ratio. The tumor cell nucleus and membrane were confirmed by Hoechst 33342 (Figure
4.3A-C) and DIOC18 (Figure 4.3D-E) staining, respectively. Adipocytes were identified
by giant LDs within cells (Figure 4.2B), and blood vessels were recognized by tubular
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Figure 4.2 CARS and SFG imaging of significant components of the
mammary tumor and stroma (Red: CARS; Green: SFG). (A) CARS image of
tumor cells whose signal comes from lipid-rich cell membrane. (B)
Adipocytes among dense collagen fibrils. (C-D) 3D images of blood vessels
surrounded by parallel collagen fibrils. Scale bars: 25 µm.

structures shown in depth-resolved CARS images (Figure 4.2C-D), which were
confirmed by FITC-IB4 labeling (Figure 4.4). In addition to various types of cells, we
observed dense type I collagen fibrils surrounded by adipocytes (Figure 4.2B) and
paralleled with blood vessels (Figure 4.2C-D). These findings demonstrate that
CARS/SFG imaging allows label-free evaluation of mammary tissue architecture,
including cell shape and arrangement, as well as collagen organization.
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4.3.2

CARS/SFG Imaging of Normal Tissue, Adenoma, and Adenocarcinoma of
Mammary Glands in Histology Samples

To determine whether CARS/SFG imaging could identify normal mammary gland,
adenomas, and adenocarcinomas, we studied well-defined histology slides of mammary
tissues. While considerable forward CARS signals arose from the unfilled areas on
histology slides, including LDs within adipocytes, cell nuclei gave significant negative
contrast because Haematoxylin, which was used for cell nuclei staining, absorbed most of
the incident light. For the same reason, eosin-stained cytoplasm and ECM can be seen
under CARS microscopy. Thus, CARS enabled us to depict the morphology of the
histological specimen. SFG was used for selective imaging of type I collagen fibrils.
Compared with histological images of normal mammary gland, adenomas and
adenocarcinomas (Figure 4.5A-C, respectively), the merged CARS and SFG images of
corresponding histology slides (Figure 4.5D-F, respectively) specifically depicted
morphological characteristics of normal mammary gland, mammary adenomas and
adenocarcinomas. Density and organization of collagen fibrils surrounding epithelial cells
provided the first identification marker. In the normal mammary glands and mammary
adenomas, dense wavy collagen fibrils paralleling the ductal profile formed an integral
scaffold to support the ductal cells. In contrast, the tumor mass in mammary
adenocarcinomas was surrounded by thin and disorganized collagen fibrils. In addition,
the extent of cell proliferation could be used as the second identification marker. The
ductal epithelium formed a single layer in normal mammary gland, but proliferated as
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Figure 4.3 Confirm CARS observation of tumor cells by Hoechst33342 and
DIOC18 labeling. (A, D) CARS image of tumor cells whose signal comes
from lipid-rich cell membranes. (B) TPEF image of tumor cell nuclei labeled
with Hoechst33342. (C) Merged image of A and B (red: CARS; green: TPEF).
(E) TPEF image of tumor cell membrane labeled with DIOC18. Scalar bars:
25 µm.

multilayered epithelium in mammary tumors. Moreover, whereas the tumor mass was
still localized in adenomas, tumor cells proliferated out of control and invaded the
surrounding stroma in adenocarcinomas.

4.3.3

CARS/SFG Imaging of Intact Normal tissue, Adenoma, and Adenocarcinoma of
Mammary Glands
The criteria established in the CARS/SFG images of histology slides were used to

study unstained mammary tissues. The label-free CARS and SFG images of the intact
normal mammary gland are shown in Figure 4.6A, which reflects the similar features
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Figure 4.4 Confirm CARS observation of blood vessels by FITC-IB4 labeling.
(A) CARS image of tumor cells and endothelial cells. (B) TPEF image of a
blood vessel labeled with FITC-IB4. (C) SFG image of collagen fibrils. (D)
CARS image (red) of the blood vessel is colocalized with TPEF (green) image.
The blood vessel is protected by collagen fibrils (blue). Scalar bars: 25 µm.

observed from standard light microscopy of histological slides (Figure 4.6B). Based on
these images, we were able to observe a single layer of epithelia on the innermost part of
the duct. Bunches of mature collagen with a wavy fibrillar appearance tend to wrap
concentrically around the duct and show a typical orientation of their long axis
paralleling the duct. Outside the collagen are orderly arranged adipocytes with one giant
LD per cell. In the zoom-in CARS image of the ductal cells, the single layer of columnar
epithelium was seen with single-cell resolution (Figure 4.6C).
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Figure 4.5 Validating CARS/SFG imaging as a tool to identify the normal
mammary gland, mammary adenomas and adenocarcinomas. (A-C) H&E
stained histology images of normal mammary gland, mammary adenoma and
adenocarcinoma, respectively. Scale bars: 100 µm. (D-F) CARS and SFG
images of histology slides from normal mammary gland, mammary adenoma
and adenocarcinoma, respectively. Scale bars: 75 µm.

We further characterized mammary tumor tissues with the CARS/SFG imaging
system. 3D images of adenomas showed that abundant wavy collagen fibrils formed a
smooth outer contour that concentrically wrapped around the small cluster of tumor cells.
These cells had a low cuboidal shape with enlarged nuclei and were in close proximity to
each other (Figure 4.6D-F). The well-defined collagen boundary around the localized
tumor mass was indicative of the tumor’s benign nature. On the contrary, tumor cells in
the adenocarcinoma showed a ragged contour without an organized concentric wrap of
collagen (Figure 4.6G-I). These malignant tumor cells had a similar shape and size as
tumor cells in the adenoma, but they had more invasive potential with the assistance of
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Figure 4.6 Label-free CARS and SFG imaging of normal mammary gland,
mammary adenoma and adenocarcinoma in intact tissues (Red: CARS; Green:
SFG). (A-C). Representative CARS and SFG images of unstained normal
mammary gland ex vivo. Single-layer ductal cells are wrapped concentrically
by bunches of wavy collagen fibrils (A, asterisk). Outside are orderly arranged
adipocytes marked with “a” in A. The same features observed in intact tissue
(A) are confirmed by the corresponding histological pattern (B). The box
shown in A was magnified in C, which permits the single-cell resolution
imaging of ductal cells (arrow head). Scale bars: 50 µm. (D-F) 3D images of
adenoma show that abundant wavy collagen fibrils form a smooth organized
outer contour (arrow heads) to concentrically wrap around the localized tumor
mass. (G-I) Straight collagen fibrils usually observed either within (G, arrow)
or perpendicularly against (H, I, asterisk) the tumor mass. The triangles in H
delineate the ragged collagen boundary of tumor mass. Scale bars: 25 µm.
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4.3.4

Quantitative Analysis of Collagen Density Surrounding Tumor Mass

Figure 4.7 Quantitative analysis of collagen density surrounding tumor mass.
Analysis of three pairs of adenoma and adenocarcinoma shows that adenoma
has an average 4-fold higher collagen density surrounding tumor mass than
adenocarcinoma. (Inset: simplified model that defines the dimensions of
imaging; see details in Experimental Section.)

straight collagen fibrils usually observed either within (Figure 4.6G) or perpendicularly
against (Figure 4.6H-I) the tumor mass. The straight collagen fibrils may act as
“highways” enabling malignant tumor cells to migrate and invade towards the
vasculature [381]. In addition to collagen organization, another factor that distinguished
adenoma from adenocarcinoma was collagen density surrounding the tumor mass. A
significant reduction of collagen density was observed in adenocarcinomas relative to
adenomas. The mammary tumor status identified by the CARS/SFG imaging system was
verified by the histological analysis of corresponding mammary tissues blindly.
To confirm that collagen density surrounding the tumor mass decreases in
aggressive tumors, we quantitatively analyzed the collagen density surrounding
adenomas and adenocarcinomas. Because SFG intensity is directly correlated with the
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concentration of type I collagen fibrils, we evaluated the relative collagen density of a
tissue based on total SFG intensity. To systematically compare the collagen density
between adenoma and adenocarcinoma, we defined a fixed analysis volume starting from
the tumor mass-collagen interface and collected total SFG signals from six volumes in
the mammary tumor tissues of each tumor (see Experimental Section; Figure 4.7).
Consistent with our observation, quantitative analysis of SFG intensity indicated that
mammary adenocarcinomas show a decrease in collagen density surrounding tumor mass
by an average of 4-fold relative to mammary adenoma.

4.4

Discussion

We have distinguished normal mammary epithelial cells and mammary tumor
cells based on the morphological information provided by CARS imaging. Whereas
normal epithelial cells grew in a columnar shape with small nuclei and formed a single
layer, tumor cells developed a round shape with large nuclei and proliferated into a
multilayer cluster (Figure 4.6). Thus, our identification of tumor cells is based on the
morphology and arrangement of epithelial cells. Because the CARS signals are generated
from symmetric CH2 stretch vibration, our method does not require any labeling and
therefore avoids the common problem of photobleaching in fluorescence microscopy.
Although CARS was able to identify normal epithelial cells and tumor cells, it
could not differentiate adenoma and adenocarcinoma by itself. Thus, we integrated
CARS with SFG on the same platform, so that we were able to take advantages of both
CARS and SFG to comprehensively characterize mammary tissues. SFG has been used to
specifically image type I collagen fibrils [382, 383]. Here, SFG specifically recognized
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dense wavy collagen fibrils in normal mammary gland and mammary adenoma, as
opposed to the thin straight collagen fibrils in mammary adenocarcinoma (Figure 4.6).
These findings suggest that, in addition to morphological characteristics of epithelial cells,
density and organization of type I collagen fibrils can also be evaluated as a crucial
signature of tumor progression. Therefore, simultaneous CARS and SFG imaging of
mammary tissues can indeed offer more comprehensive information compared to each
individual technique. Our results have demonstrated that multimodal CARS/SFG imaging
is able to accurately differentiate adenoma from adenocarcinoma in rat mammary tissues,
based on morphology and arrangement of epithelial cells and 3D organization of type I
collagen fibrils.
Several previous studies have shown that aberrations in type I collagen production
and degradation have become one of the hallmarks of tumor stroma [384]. The
observation of reduced collagen density in adenocarcinoma relative to adenoma is
consistent with previous findings on proteases that degrade ECM in tumor environment
[384]. More interestingly, Provenzano et al. defined tumor-associated collagen signatures
to locate and characterize mammary tumors [385, 386]. In particular, Provenzano et al.
claimed that collagen reorganization at the tumor-stromal interface facilitates local
invasion [385]. So far, however, few studies have discussed straight collagen fibrils
present in mammary adenocarcinoma. It is possible that collagenases and proteases play
important roles in the formation of straight collagen fibrils to further facilitate tumor cell
migration and invasion. The mechanisms underlying straight collagen formation need to
be addressed in the future.
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In this work, multimodal CARS/SFG imaging has shown the potential of
intraoperative assessment of tumor margins. With a penetration depth of tens of microns
and subcellular spatial resolution, CARS/SFG imaging provides a new contrast other than
histology and enables us to identify tumor cells and their malignancy near the margin.
Unlike histology, CARS/SFG imaging does not need any labeling agents, so that
decisions can be made during the surgery. As a result, most normal tissues can be
maintained with a negative margin. Furthermore, improvements in intraoperative margin
assessment can significantly reduce local recurrence and distant metastasis induced by
positive margins and re-excisions usually observed after lumpectomy. In order to achieve
intraoperative margin assessment in situ by CARS/SFG imaging, the imaging system
needs to be more compact by application of fiber lasers. The compact CARS/SFG
imaging system could assist pathologists in making decisions and help surgeons remove
entire malignant tumor tissues, while saving as much normal tissues as possible, within a
single surgical procedure.
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CHAPTER 5. OUTLOOK

5.1

Cholesterol Metabolism in Cancer

Our study has identified cholesterol esterification as a potential marker and
therapeutic target of advanced PCa. Our next step, therefore, is to first validate the
presence of altered cholesterol metabolism in human PCa patient specimens and prove
the accumulation of CEs correlates with the clinical outcomes of PCa patients. We will
then elucidate the mechanism linking cholesterol metabolism with cancer aggressiveness,
and evaluate the therapeutic benefit of CE depletion in preclinical animal models of PCa.
At the completion of this project, it is our expectation that we will have provided strong
evidence to support the concept that inhibition of cholesterol accumulation is a viable and
potentially attractive therapeutic intervention strategy to treat advanced PCa. Notably,
several small molecule inhibitors of cholesterol accumulation, e.g. avasimibe, have been
approved by FDA to treat atherosclerosis but failed due to the lack of effectiveness. Our
proposed study would demonstrate a novel use of existing drugs to treat advanced PCa,
and it is anticipated that preclinical studies and/or clinical trials will follow shortly after
the completion of this project. Ultimately, the adoption of such strategy will substantially
improve the clinical outcome for metastatic PCa patients that are resistant to hormone
therapy. Our deeper mechanistic study will contribute to the understanding of
dysregulated cholesterol metabolism in advanced PCa, which in turn provides the
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biological foundation of targeting cholesterol accumulation for treatment of metastatic
PCa.
The long term goal of our project on cholesterol metabolism in cancer is to
develop strategies that enable early diagnosis of aggressive tumors using elevated
cholesterol metabolites as molecular markers, as well as suppression of cancer
aggressiveness by modulating cholesterol metabolism pathways. Because the PI3K
pathway is hyperactivated not only in advanced PCa, but also in many other human
cancers, including brain, breast, renal, lymphocyte, cervical, and lung [67], cholesterol
accumulation might be a common characteristic of PI3K-driven cancers. Future analysis
of various types of human cancer tissues will validate whether CE is indeed a hallmark of
PI3K-driven cancers, and whether CE can be used as a prognostic marker to predict
cancer aggressiveness. Future elucidation of the molecular mechanisms by which PI3K
pathway differentially regulates cholesterol metabolism in cancer cells from multiple
tissues of origin will determine whether CE is a compelling drug target across multiple
cancer types.

5.2

Membrane Lipids in Cancer

Based on the results of our study, we expect that analysis of apical polarity in live
human mammary acini using Raman spectromicroscopy provides an effective screening
platform to identify risk or protective factors that initiate or prevent breast cancer. We
will achieve this goal with the following two steps.
The first step is to identify breast cancer risk and protective factors using Raman
based screening platform. Dietary fatty acids and adipokines have been associated with
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breast cancer development [42, 387] Fatty acids are delivered to mammary cells mainly
by uptake of LDL [263]. Dietary interventions of fatty acids can lead to rapid and
potentially beneficial changes in ω3/ω6 PUFA ratio of serum and breast adipose tissue
[345, 346]. The adipokines are a number of adipocyte-secreted polypeptides that have
been associated with obesity and insulin resistance [42, 387]. However, a consensus is
lacking on the impact of certain dietary fatty acids or adipokines on primary prevention
of breast cancer [42, 388-390]. Our study has shown the capability of Raman
spectromicroscopy to monitor the dynamic changes of apical polarity of the same acini
over time. We will continue to test if Raman based screening platform could accurately
and effectively determine the effects of a panel of dietary fatty acids and adipokines on
apical polarity of mammary acini. Combinations of identified risk and potential
protective factors will be further assessed to evaluate the preventative potential of the
protective factors.
The second step is to reveal the impact of the identified risk and protective factors
on the expression of apical polarity-associated genes. Recent findings have revealed that
the status of apical polarity influences two genes of particular interest: PDPK1 and CDS1
(unpublished data, Lelièvre lab). PDPK1 functions downstream of PI3K through
PDPK1's interaction with membrane phospholipids.[391] Although PDPK1 is known to
be overexpressed in breast cancer,[391, 392] it has just been found to be upregulated
when apical polarity is disrupted by AGA reagent, an inhibitor of gap junctional
intercellular communication. CDS1 is an important precursor for the synthesis of
phosphatidylinositol, whose phosphorylation plays an important role in lipid signaling
[393]. Down-regulation of CDS1 has just been linked to loss of apical polarity induced
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by AGA reagent. By simultaneously measuring membrane lipid phase and expression of
PDPK1 or CDS1 of the same acini over time, we will evaluate the change of PDPK1 or
CDS1 expression when apical polarity is altered by identified risk factors or when apical
polarity is restored by combining protective factors with the risk factors. This endeavor
will determine whether PDPK1 or CDS1 is involved in the apical polarity alteration
induced by the risk factors. The involvement of apical polarity-associated genes builds up
a molecular basis for the impact of risk and protective factors on apical polarity of
mammary acini, which may assist future mechanistic studies.
Finally, our approach could be extended to a multi-well plate on a dual scanning
Raman spectromicroscope for high-throughput screening of numerous compounds and
drugs. Future systematic study along this direction will help the design of better primary
prevention strategies to reduce breast cancer incidence.
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